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ABSTRACT 
 
Cytochrome P450 monooxygenases are ubiquitous in nature, catalyzing a variety 
of oxidative transformations.  Recent work has shown that the bacterial P450 PikC can 
catalyze the regioselective hydroxylation of both small molecule and larger 
macrolactone ring systems via a unique anchoring mechanism.  The catalytic versatility 
of PikC, however, remains limited primarily to hydroxylation reactions.  Further research 
into the activity of mixed function P450s could therefore expand upon the use of 
enzymes as biocatalysts.   
Chapters 1-3 of this thesis focus on the rapid synthesis of a series of analogs of 
tirandamycin, the natural substrate of the multi-functional P450 TamI, to access novel 
oxidation products using either PikC or TamI.  Investigation into these biocatalytic 
systems explores whether PikC can install multiple types of oxidative functionality within 
the bicyclic core of tirandamycin as well as probes the utility of TamI as a mixed function 
biocatalyst for site-selective oxidation of unnatural substrates. 
Chapter 4 of this thesis describes a case study of a laboratory exchange 
between a chemistry graduate student from a R1 research institution and an 
undergraduate student involved in summer research at a primarily undergraduate 
institution (PUI).  Interviews and observations were used as a means to document 
learning of participants.  Findings from this study show an increase in personal and 
 xx 
professional growth among exchange students and provide support for the design and 
implementation of these programs by others. 
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CHAPTER I 
Isolation, Biological Activity & Biosynthesis of Tirandamycin 
 
1.1 Tetramic Acid Natural Products 
 The antibiotic tirandamycin is one of several naturally occurring tetramic acids 
that are characterized by the inclusion of a 2,4-pyrrolidinedione ring system (Figure 1.1).  
While this functional motif has been known since its original synthesis in the early 
twentieth century, the pharmacological importance of the tetramic acid was not well 
understood until the isolation of bio-active tetramic acid-containing natural products in 
the 1960s.1 Owing largely to their breadth in structural and biological diversity, tetramic 
acids have now become a topic of renowned interest to many synthetic and medicinal 
chemists. 
Tirandamycin is one of several known dienoyltetramic acids which contain a 1-
oxopentadienyl tether linking the tetramic acid at the C3 position to a bicyclic ketal 
moiety.  Other structurally related members of this family vary in their substitution 
around both the bicyclic and tetramic acid ring systems.  For example, the first reported 
dienoyltetramic acid streptolydigin,2 (Figure 1.1) features a spirocyclic epoxide 
appended to the bridge of the bicycle and a glycosylated tetramic acid bearing an amide 
side chain.  Tirandalydigin,3 which can be considered a structural hybrid of tirandamycin 
and streptolydigin, maintains the same bicyclic moiety as streptolydigin, but lacks the 
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presence of further functionalization around the tetramic acid center.  Nocamycins I and 
II,4,5 on the other hand, possess the same unsubstituted acyl tetramic acid subunit 
connected to a structurally distinct fused oxolane ring system. 
 
Figure 1.1 – Select Examples of Tetramic Acid Natural Products 
 
While the dienoyltetramic acids have received notable attention due to the 
antibiotic activity conferred by the presence of the 3-dienoyl subunit, tetramic acid 
natural products display a diverse array of structural and biological properties.  The 
fungal metabolite Equisetin, for example, was found to be a novel in vitro HIV-1 
integrase inhibitor, leading to its evaluation as a potential chemotherapeutic.6 
Furthermore, -cyclopiazonic acid is a tetramic acid-containing mycotoxin that displays 
disparate biological effects, including alteration of neurotransmitter levels,7 inhibition of 
calcium uptake,8,9 and antioxidant activity.10 
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The remainder of this chapter will summarize the isolation, biological activity and 
proposed biosynthetic pathways of tirandamycin, which provide a foundation for the 
work presented in chapters 2 and 3 of this thesis. 
 
1.2 Bacterial Isolation of Tirandamycin 
 Tirandamycin was first isolated by Meyer in 1971 from the terrestrial bacterium 
Streptomyces tirandis.11 At the time, the structure was thought to be similar to that of 
streptolydigin, although the absolute configuration of tirandamycin was not confirmed 
until later in 1973 from the x-ray crystal of the p-bromophenacyl ester of tirandamycic 
acid.12 Three years later, tirandamycin was isolated again from Streptomyces flaveolus, 
along with a closely related natural product bearing an additional hydroxyl group.13 
Once it was confirmed that two unique variants of tirandamycin had been identified, the 
original and newly isolated structures were distinguished as tirandamycin A (TirA) and B 
(TirB), respectively (Figure 1.2). 
Subsequent work by Sherman and co-workers utilized XAD-16 resin to harvest 
two new secondary metabolites, tirandamycin C (TirC) and D (TirD), from the 
tirandamycin pathway.14 These compounds, which were obtained from early stationary 
phase fermentation of the marine isolate Streptomyces sp. 307-9, were hypothesized to 
be key biosynthetic intermediates which precede TirA and TirB in the biosynthesis of 
tirandamycin.  This was most clearly evidenced by the isolation of TirA and TirB in the 
absence of adsorbent resin, which was capable of sequestering and protecting TirC and 
TirD from further enzymatic modification.  Later in 2011, Sherman et al. identified 
another tirandamycin congener, tirandamycin E (TirE), while further elucidating the role 
of the enzymes TamI and TamL in the oxidative tailoring of tirandamycin.15 When TirC 
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was incubated with the recombinant P450 TamI, they observed the formation of the C10 
hydroxyl to give TirE instead of TirD.  These experiments, in conjunction with the 
characterization of the biosynthetic gene cluster from Strep. sp. 307-916, provided initial 
insight into the putative biosynthetic pathway from this bacterial species, which involves 
a multi-functional iterative cascade which resolves the differences in oxidative 
complexity leading from TirC to TirB.  The more recent isolation of tirandamycin K 
(TirK), the first linear tirandamycin derivative, from a tamI disruption mutant strain of 
Strep. sp. 307-9, has since added to this understanding of tirandamycin biosynthesis, 
which will be explained in more detail in section 1.4.2 below.17 
 Over the past decade work from Ju and Shen has contributed to the identification 
of several additional tirandamycin species.  In 2010 TirA and TirB were also isolated 
from Strep. sp. SCSIO 1666, a marine-derived actinomycete bacteria obtained from 
samples of sediment from the South China Sea.18 This prompted further investigation of 
the tirandamycin gene cluster from Strep. sp. SCSIO 1666,19 which was shown to share 
similar organization to that of Strep. sp. 307-9.  Gene inactivation experiments of P450 
encoding trdI led to the accumulation of TirC, along with a trace amount of a new 
product labeled by Ju and co-workers as tirandamycin C2.  Given that tirandamycin C2 
is the C10 epimer of TirE, for the remainder of this thesis document tirandamycin C2 will 
be referred to as (R)-TirE, with TirE alluding to the S stereoisomer isolated by Sherman 
in 2011.15 This S stereoisomer (labeled as tirandamycin F by Ju) was also isolated 
around the same time from Strep. sp. SCSIO 1666 following further gene disruption 
studies involving a trdL mutant.20 Without the use of XAD-16 resin however, a new 
compound, tirandamycin F2 (TirF2), was produced instead. (Note that this is not the 
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name given by Ju, who refers to this congener as tirandamycin E.)  Pre-tirandamycin, 
an early biosynthetic intermediate which is hypothesized to precede TirC, was isolated a 
year later through in vivo trdE inactivation.21 
 
Figure 1.2 – Isolated Congeners of Tirandamycin 
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 Tirandamycin has also been isolated from a bacterial species of terrestrial origin, 
Strep. sp. 17944.22,23 A high-throughput drug discovery screen reported in 2011 by 
Shen and others led to the recovery of three unique tirandamycins, TirF1, TirF2 and 
TirG, from this bacterial strain in addition to TirA and TirB.  (Note that TirF1 and TirF2 
are referred to by Shen as TAM F and TAM E, respectively.)  Interestingly, TirF1 and 
TirF2 share the same oxidative modification, with TirF1 lacking the C18 methyl that has 
been present in all other isolated triandamycin congeners to date.  A year later, growth 
medium optimization led to the isolation of three additional biosynthetic intermediates, 
TirH, TirI, and TirJ from Strep. sp. 17944.  While TirH was identified as the C18 
hydroxylated analog of TirF2, spectral characterization of Tir I and TirJ showed the 
presence of a glucose sugar appended to the bicyclic ketal moiety, giving TirF2-10--D-
glucoside and TirB-18--D-glucoside. 
 More recently it has been reported that TirA and TirB have also been isolated by 
Zhu et al. from another marine-derived bacterial species, Strep. sp. 17944, obtained 
from samples of the marine sponge Gelliodes carnosa from the South China Sea.24 
Notably, TirA and TirB were isolated alongside other structurally diverse natural 
products including a new peptide antibiotic, quinomycin G, and TirB was isolated as its 
tautomer in the 1-keto-4’-enol form. 
 
1.3 Biological Activity of Tirandamycin and Related Tetramic Acid Antibiotics 
1.3.1 Antibiotic Activity 
 Shortly following the isolation of TirA by Meyer11, microbiologists became 
interested in investigating its biological activity, particularly due to its structural similarity 
to the known antibiotic streptolydigin.  Not surprisingly, TirA was also found to inhibit the 
 7 
growth of a variety of Gram-positive bacteria, although its potency was markedly less in 
comparison.25,26 Later in 2009 this activity was evaluated across other biosynthetic 
intermediates in the tirandamycin pathway.14 In a study conducted by Sherman and co-
workers which measured activity against vancomycin-resistant Enterococcus faecalis 
(VRE), TirA was found to be the most effective antibiotic with a minimum inhibitory 
concentration (MIC) of 2.25 M in comparison to TirB (MIC = 100 M), TirC (MIC = 110 
M) and TirD (MIC = >9 M).  This showed that while oxidative modification to install 
the C10 ketone and C11/C12 epoxide results in an increase in potency, the introduction 
of the C18 hydroxyl attenuates this activity.  Notably, tirandamycin A is also the most 
readily isolated tirandamycin congener,15 suggesting that the tirandamycin pathway is 
tuned towards the production of its most bioactive intermediate.  Furthermore, 
measurement of the antibiotic activity of linear TirK against several Gram-negative and 
Gram-positive strains of bacteria showed a significant decrease in potency with respect 
to TirC, indicating that the tirandamycin bicycle likely contributes to its antmicrobial 
properties.17 
  Early studies on the antibacterial activity of TirA prompted further investigation 
into its biological mechanism.  Work by Reusser25,27 showed that similar to 
streptolydigin, TirA inhibits the de novo synthesis of RNA in E. coli, interfering with the 
chain initiation and chain elongation processes catalyzed by RNA polymerase (RNAP).  
Reusser also reported that this inhibition was caused by interactions of tirandamycin 
with the polymerase itself, rather than the DNA template or template-enzyme complex.  
An analogous effect, however, was not observed on mammalian RNAP derived from rat 
liver. 
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 More extensive research has explored the details of RNAP inhibition by 
streptolydigin, which as mentioned above, is hypothesized to be related to the 
mechanism of action of tirandamycin.  Crystal structures of the streptolydigin-RNAP 
complex28,29 have revealed that three main RNAP structural elements come in contact 
with streptolydigin: the streptolydigin (Stl) pocket and bridge helix, which interact with 
the streptolydigin bicycle and its 1-oxopentadienyl tether, and the trigger loop region, 
which associates with streptolydigin’s highly substituted tetramic acid (Figure 1.3 and 
1.4).  Notably, the Stl tetramic acid moiety is also positioned near the DNA non-template 
strand in the transcription elongation complex (Figure 1.3), suggesting that incorporation 
of a DNA binding substituent could increase the potency of future analogs of 
streptolydigin. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 – Modeled Interactions of Streptolydigin (Stl) with RNAP Transcription 
Elongation Complex28 
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Figure 1.4 – Structural Basis of Inhibition by Streptolydigin (Stl) - Bridge helix and 
trigger loop conformational differences between RNAP and RNAP-streptolydigin 
complex28 (In figure B the white sphere represents the Mg2+ active-center and the green 
is Streptolydigin.) 
 
 It has been proposed in the literature that RNAP function is dependent on the 
alternation of the RNAP bridge helix between its straight and bent conformational 
states.30–33 Comparison of Stl-bound and unbound RNAP illustrates the impact that 
streptolydigin has on these active site conformations, forcing the bridge helix to adopt a 
straight rather than bent orientation (Figure 1.4).28 This also causes the opening of the 
trigger loop, which must be displaced in order to accommodate Stl, leading to an 
inactive configuration of the elongation complex.34 It is therefore likely that streptolydigin 
binds to and stabilizes RNAP in this orientation, inhibiting the conformational cycling 
thought to be necessary for RNAP function. 
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 Recently Dairi disclosed that tirandamycin also inhibits the synthesis of 
menaquinone (MK), or vitamin K2, in Bacillus halodurans C-125.35 MK is essential to the 
survival of many bacterial strains, being produced via one of two different pathways 
from a common biochemical intermediate (Scheme 1.1).  TirA and TirB were found to 
exclusively target the futalosine pathway, likely disrupting MK synthesis following the 
formation of 1,4-hydronaphthoquinone-6-carboxylic acid.  Notably, the futalosine 
pathway is the operative pathway in Helicobacter pylori, Gram-negative bacteria linked 
to the development of ulcers and stomach cancer.  Since humans and useful intestinal 
bacteria lack this alternative pathway, futalosine pathway inhibitors such as 
tirandamycin can inspire the design of novel gastrointestinal therapeutics. 
 
Scheme 1.1 – Inhibition of Futalosine Pathway by Tirandamycin (R = isoprenoid side 
chain of varying length) 
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1.3.2 Antiparasitic Activity  
 As alluded to earlier, the isolation of tirandamycin from Strep. sp. 17944 was the 
result of a natural product drug discovery program which identified Strep. sp. 17944 as 
an active strain against the filarial parasite Brugia malayi.22 Specifically, TirB inhibits B. 
malayi asparaginyl-tRNA synthetase (AsnRS), which is expressed in all developmental 
stages of the parasite and is necessary for its survival.  Infection by B. malayi 
roundworms causes disruption of the lymphatic system in humans, leading to the 
development of the tropical disease lymphatic filariasis.36 Today, 856 million people in 
52 countries remain at risk of suffering from lymphatic filariasis, creating a need for new 
antifilarial drugs to combat this global health problem. 
 Shen, Kron and co-workers evaluated the inhibitory activity of tirandamycin 
against B. malayi AsnRS through a “pretransfer editing assay” designed to measure 
AsnRS activity through pyrophosphate production.37 While all other tirandamycin 
congeners (TirA, TirF1, TirF2, TirG, TirH, TirI and Tir J) showed no measurable impact 
on phosphate generation, TirB was found to selectively inhibit B. malayi AsnRS over 
human AsnRS with an IC50 of 30 M.22,23 This suggests the high level of oxidative 
tailoring present in TirB is a critical pharmacophore, as reduction of the C10 carbonyl 
(TirH) or glycosylation of the C18 hydroxymethyl (TirJ) completely eliminates any 
observed antifilarial activity. 
TirB was also shown to kill B. malayi worms in vitro with a greater efficiency than 
albendazole, an approved drug for the treatment of lymphatic filariasis.  While more 
than ten days were needed for 100 M albendazole to kill adult worms, less than 24 
hours was needed for TirB (IC50 = 1 M) to cause filarial death at the same 
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concentration.   This further illustrates the potential for TirB to serve as a lead scaffold 
for future antifilarial drug development, which can help stop the spread of parasitic 
infection and contribute to the global eradication of lymphatic filariasis. 
 
1.4 Biosynthesis of Tirandamycin 
 To date, the tirandamycin biosynthetic gene cluster has been independently 
cloned and characterized from two different bacterial species, Strep. sp. 307-916 and 
Strep. sp. SCSIO1666.19 Both gene clusters share a similar organization, containing a 
hybrid polyketide synthase (PKS) / non-ribosomal peptide synthetase (NRPS) 
assembly-line system which is collinearly organized and is flanked by coding regions for 
two oxidative tailoring enzymes.  This high level of similarity is also shown in the 
proposed biosynthetic pathways of these two bacterial species, which include protein 
homologs with 98% to 100% sequence identity.  The remainder of this chapter will focus 
primarily on the tam gene cluster and the biosynthesis of tirandamycin from Strep. sp. 
307-9, but will incorporate discussion of the biosynthetic pathways proposed by Ju and 
Shen when necessary to account for the formation of tirandamycin congeners F-J. 
 
1.4.1 Biosynthesis of Tirandamycin C 
 Type 1 polyketide synthases are large, modular proteins responsible for the 
incorporation and modification of short chain acyl groups into a growing polyketide chain 
The tirandamycin biosynthetic cluster consists of three PKS genes (tamAI, tamAII and 
tamAIII), which build the skeletal framework of tirandamycin through the successive 
condensation of malonyl-CoA and methylmalonyl-CoA building blocks (Scheme 
1.2).16,17 
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Scheme 1.2 – Hybrid PKS-NRPS Assembly Line17
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A non-ribosomal peptide synthetase encoded by the tamD terminal module then allows 
for the introduction of glycine to the nascent polyketide chain.  Unlike other assembly 
line enzymes, however, TamD lacks a C-terminal releasing domain, leaving the chain 
release mechanism of tirandamycin from the terminal module unclear.  Both Sherman16 
and Ju19 have proposed that this step involves the non-enzymatic attack of the activated 
C-3’ methylene on the PCP thioester to give the resulting tetramic acid (Scheme 1.2), 
although this has not yet been confirmed experimentally. 
 Several different mechanisms have been suggested in the literature regarding 
the biosynthesis of the tirandamycin bicycle.  Sherman initially hypothesized that 
cyclization occurs on the predicted linear intermediate that is theoretically formed 
following chain release from the NRPS module (Scheme 1.2).16 Identification of the 
terpene synthase homolog tamF led to the assumption that this happens in a manner 
similar to terpene cyclization, involving protonation of the C8-C9 double bond followed 
by addition of the hemiketal hydroxyl at C9 (Scheme 1.3).  A tamF disruption strain, 
however, did not lead to the accumulation of pre-cyclization intermediates as would be 
predicted under this mechanism, making it unlikely that bicyclic ketal formation occurs in 
this fashion. 
Recently, isolation of the linear tirandamycin derivative TirK prompted a second 
look at the proposed biosynthetic pathway of tirandamycin.17 Notably, TirK retains the 
C9 hydroxyl group which was originally thought to be removed by the module 3 
dehydratase domain (DH3, Scheme 1.2).  This suggests another possible role for DH3, 
such as involvement in the formation of the bicyclic ketal, as initially proposed by Ju et 
al.19 In this mechanism, the C9 hydroxyl, instead of the C7 hydroxyl, takes part in the 
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initial cyclization event, followed by dehydration and attack of the C7 alcohol on the 
resulting oxonium ion (Scheme 1.4).  Incorporation of the C9 oxygen is in agreement 
with previous oxygen labeling studies on the biosynthetic pathway of streptolydigin, 
providing further support for this mechanism.  
 
 
 
 
 
 
 
Scheme 1.3 – Proposed Mechanism of Bicycle Formation by TamF Terpene Synthase 
  
Since the participation of DH3 would require transfer of the pentaketide 
intermediate back to module 3, the module 4 ketoreductase (KR4) also must be 
considered as the active site for catalysis (Scheme 1.4).  Additionally, the 
stereochemistry of the C9 hydroxyl in TirK is opposite of what is expected by a B-type 
ketoreductase domain (KR3), suggesting the reduction proceeds with non-canonical 
stereoselectivity to form both R and S epimers.  This provides rationale as to why TirK 
may avoid cyclization, presuming the 9S configuration prevents the intermediate from 
adopting the correct orientation for nucleophilic addition. 
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Scheme 1.4 – Plausible Mechanism for the Synthesis of the Tirandamycin Bicycle17
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 Lastly, following release from the terminal module, pre-tirandamycin is converted 
to TirC via a post-assembly line elimination reaction catalyzed by the TrdE glycoside 
hydrolase (Scheme 1.2).21 This likely occurs via the transient breakdown of the 
tirandamycin bicycle to form an acidified oxonium intermediate, which subsequently is 
dehydrated by carboxylate containing residues within the active site (Scheme 1.5).  
 
 
 
 
 
 
 
Scheme 1.5 – Proposed Mechanism for C10-C11 Double Bond Formation 
 
1.4.2 Oxidative Tailoring of Tirandamycin 
 The final steps in the biosynthesis of tirandamycin involve the interplay of two co-
dependent enzymes, the cytochrome P450 TamI and TamL flavoprotein, which are 
responsible for the oxidative modification of the tirandamycin bicycle (Scheme 1.6).15 
While cytochrome P450 monooxygenases are well known for enabling a variety of 
transformations38, TamI is unique in that it is a versatile P450 which acts in tandem with 
another enzyme to install multiple functionality within a single substrate, highlighting it’s 
remarkable flexibility in substrate recognition and catalysis. 
 TamI has been shown to promote three of four sequential steps in the oxidative 
cascade of tirandamycin.  TirC is first oxidized by TamI at the C10 secondary allylic 
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position to give TirE, as discovered through the initial isolation of TirE by Sherman and 
co-workers.15 While TirE formation was observed following incubation of TirC with 
recombinant P450 enzyme, only the latter accumulated from tamI disruption strains.16  
 
 
 
 
 
 
 
 
Scheme 1.6 – Oxidative Cascade of Tirandamycin in Strep. sp. 307-9 
 
The mechanism of hydrocarbon hydroxylation by P450s is well studied in the 
literature.38,39 Formation of the active catalyst involves incorporation of molecular 
oxygen to generate a porphyrin radical cation Fe(IV) oxo species, which is facilitated by 
the addition of two single electron reducing equivalents provided by NAD(P)H (Scheme 
1.7A).  A proximal hydrogen atom is then abstracted from the substrate, followed by 
rapid recombination of the alkyl radical via a radical rebound mechanism to give the 
hydroxylated product (Scheme 1.7B).   
The minimal accumulation of downstream oxidation products from the incubation 
of TirC with TamI illustrates that while TamI is capable of catalyzing this process in vitro, 
another enzyme is likely responsible for the predominant formation of TirD.15 Indeed, 
TamL was found to be effective at converting TirE to TirD, likely through reduction of a 
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covalently bound FAD cofactor.  Crystal structures revealed tirandamycin binds in the 
active site of TamL with the bicyclic ketal moiety positioned towards FAD and the 
tetramic acid extended towards the mouth of the substrate binding cleft (Figure 1.5).  
Proximity of the C10 hydrogen towards N5 of the isoalloxazine ring is consistent with a 
hydride transfer mechanism, in which the C10 hydroxyl of tirandamycin is first 
deprotonated by a highly conserved Y447 residue.  Y136 may also participate in this 
proton transfer network to help facilitate proton abstraction through activation of Y447. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.7 – Mechanism of P450 Catalyzed Hydroxylation A: Cytochrome P450 
Catalytic Cycle B: H Atom Abstraction / Radical Rebound Mechanism 
 
Following transfer of the tirandamycin substrate back to TamI, the C11-C12 olefin 
is epoxidized to form TirA, highlighting the diverse reactivity of this multifunctional P450 
(Scheme 1.6).  TirA can then be hydroxylated by TamI at the primary C18 methyl group, 
albeit with much greater inefficiency than previous TamI catalyzed transformations  
 20 
(kcat/Km = 5.8 x 10-4 M-1 min-1 as compared to 19.3 and 3.6 M-1 min-1 for hydroxylation 
of TirC and epoxidation of TirD, respectively).15 In vitro enzymatic conversions of TirD 
and TirA with recombinant TamI provide evidence for these final two steps in 
tirandamycin biosynthesis.  
 
 
Figure 1.5 – TamL Crystal Structure A: Substrate-bound TamL Co-Crystal Structure 
(tirandamycin = blue sticks, FAD = yellow sticks). B: Superimposition of Substrate-
Bound (cyan sticks) and Substrate-Free TamL (grey sticks) C: Mechanism of 
Dehydrogenation of TirE by TamL15 
 
 
In Strep. sp. SCSIO1666 the flavin-dependent oxidoreductase TrdL was found to 
not only be responsible for the oxidation of TirE, but also the conversion of TirF2 to TirA 
(Scheme 1.8).20 This led to the proposal of an alternative biosynthetic pathway in which 
TirA is accessed through epoxidation of TirE to give TirF2 followed by subsequent TrdL-
catalyzed dehydrogenation. 
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Scheme 1.8 – C10 Dehydrogenation Catalyzed by TrdL Flavoprotein from Strep. sp. 
SCSIO1666  
 
Shen has also suggested a more complex, divergent oxidative tailoring pathway 
which takes into consideration the isolation of other highly modified tirandamycin 
congeners from Strep. sp. 17944 (Scheme 1.9).23 Both TirF and TirG, for example, 
could be formed through reduction of the C10 ketone of TirA.  Furthermore, consecutive 
hydroxylation of TirF by TamI accounts for the exclusive isolation of TirH when TirF is 
produced in high yields.  It is not clear, however, how TirI and TirJ are formed since no 
gene-encoding glucosyltransferase has been identified within the tirandamycin 
biosynthetic cluster, although Shen speculates that glycosylation of TirF and TirB may 
confer self-resistance to the bacterial organism.  Additional experimental work is needed 
in order to answer these remaining questions and validate this proposed biosynthetic 
pathway. 
 
 22 
 
 
Scheme 1.9 – Proposed Biosynthetic Pathway in Strep. sp. 17944 
 
 While significant work has been done to elucidate the role of TamI in the 
biosynthesis of tirandamycin, the underlying factors that contribute to the unique 
reactivity of multifunctional P450s are still not well understood.40 The following two 
chapters will discuss efforts towards the synthesis of a variety of analogs of 
tirandamycin and their use in evaluating the mechanism of substrate binding and 
catalysis in TamI.  These insights will not only lead to a greater appreciation of the 
functional diversity of cytochrome P450 enzymes in nature, but will be applied towards 
the development of P450 monooxygenases as versatile biocatalysts for C-H activation. 
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CHAPTER II 
Synthesis of Tirandamycin & its Analogs 
 
2.1 Total Synthesis of Tirandamycin  
2.1.1 Overview of Synthetic Strategies Towards Tirandamycin 
 
The unique structural features and biological activity14,22,23,25,26,35 of tirandamycin 
make this natural product an intriguing synthetic target. It is therefore not surprising that 
tirandamycin and other related dienoyl tetramic acids have been the focus of a variety of 
synthetic efforts since the 1980s.  Over ten different formal and total syntheses have 
been reported in the literature, the majority of which target TirA41–48, the most potent 
congener of tirandamycin.14 Nonetheless, more recent work has focused on the 
synthesis of other members of this natural product family, including TirB,49,50 TirC,51,52 
TirD50 and 10-epi-TirE.53 
Despite the variety of different approaches towards the construction of 
tirandamycin, many of these reported methods share a number of similarities.  Most 
notably, almost all of these syntheses feature a common enal intermediate (1), which 
allows for the late stage attachment of the 3-acyl tetramic acid moiety (Scheme 2.1).  
Additionally, these synthetic strategies share several complementary retrosynthetic 
disconnections, including assembly of the tirandamycin bicycle through oxidation of a 
substituted tetrahydrofuran ring (DeShong42,49 and Hatakeyama50), methyl lithium  
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Scheme 2.1 – Synthesis and Attachment of a Common Late Stage Intermediate in the 
Total Synthesis of Tirandamycin A: Attachment of Tetramic Acid via Horner-Wadsworth 
Emmons Olefination B: Overview of Various Synthetic Approaches Towards a Common 
Late Stage Intermediate 
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addition followed by subsequent ketalization of a lactone intermediate (Schlessinger41 
and Roush51), and use of a desymmetrization technique to access the synthetically 
challenging anti, anti-dipropionate stereotriad unit (Boeckman44 and Mohapatra52,53). 
 In the penultimate step of tirandamycin synthesis, coupling of a readily 
accessible phosphonate tetramic acid reagent (3) via Horner-Wadsworth-Emmons 
(HWE) olefination affords 2,4-dimethoxybenzyl (DMB) protected tirandamycin (Scheme 
2.1A).  Introduction of the benzyl substituent was found to be necessary for successful 
conversion to product, as the aldehyde was otherwise unstable under the strongly basic 
conditions necessary for condensation of the unprotected tetramic acid.41,42,44 Cleavage 
of the DMB group is then achieved through brief treatment with trifluoroacetic acid (TFA) 
to give the target compound.  
 As initially reported by Boeckman44,54 and Schlessinger,41 the requisite 
phosphonate tetramic acid 3 can be obtained in five steps from 2,2,6-trimethyl-4H-1,3-
dioxin-4-one (4, Scheme 2.2).  Allylic chlorination followed by displacement with diethyl 
phosphite provides dioxolenone phosphonate 6,55 which upon treatment with DMB 
glycine ester 7 results in the formation of  keto amide 8.  Lastly, Dieckmann 
condensation of 8 upon exposure to t-BuOK gives the desired HWE tetramic acid. 
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Scheme 2.2 – Synthesis of Phosphonate Tetramic Acid 3 
 
 
 While incorporation of the tetramic acid moiety usually involves direct coupling of 
the phosphonate tetramic acid (3, Scheme 2.1A), in a few cases cyclization of the 
tetramic acid ring occurs following its initial attachment to the tirandamycin bicycle 
(Scheme 2.3). For example, acylation of a silyl malonamidate derivative by Bartlett et 
al.45 leads to -ketoamide 11, which is then cyclized and deprotected in a manner 
similar to Boeckman44 and Schlessinger.41 On the other hand, the total synthesis of TirC 
by Mohapatra and co-workers52 involves HWE olefination of phosphonate 6 to ultimately 
furnish the DMB-protected natural product. 
 The remainder of this chapter will include a brief description of the first synthetic 
routes to TirA by DeShong42 and Schlessinger,41 followed by an account of a more 
recent approach to TirC.51 This latter work by Roush motivated our efforts towards an 
abbreviated synthesis of various analogs of the tirandamycin bicycle, which were 
subsequently used as unnatural substrates in a variety of bioenzymatic reactions 
(Chapter 3). 
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Scheme 2.3 – Alternative Methods for Tetramic Acid Incorporation 
 
 
2.1.2 Total Synthesis of TirA by DeShong and Schlessinger 
 
Two separate accounts on the total synthesis of TirA were reported concurrently 
in 1985 by the DeShong42 and Schlessinger41 research groups, making them seminal 
efforts towards the synthesis of tirandamycin. Both publications featured two different 
approaches en route to late stage intermediate 1A, each of which has influenced the 
development of later syntheses of this class of natural products (Scheme 2.1). 
The synthesis reported by DeShong et al. affords racemic TirA in 12 steps from 
simple starting materials (Scheme 2.4).42 Lithiation of 2,3-dimethylfuran followed by 
condensation with aldehyde 1356 gave a 1:1 mixture of diastereomers which were 
separated by column chromatography.  The desired stereoisomer, 14, was then 
oxidized with m-CPBA to yield pyranone 15, a key intermediate towards construction of 
the 2,9-dioxabicyclononane ring system.  BF3-Et2O was found to readily catalyze the 
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successive removal of the silyl ether protecting group from 15, inducing cyclization to 
the bicyclic ketal.   
The next several steps of DeShong’s synthesis focus on incorporation of the 
requisite epoxide.  Since direct epoxidation of the electron deficient olefin was low 
yielding, a circuitous route involving NaBH4 reduction of the enone followed by 
subsequent benzyl ether removal was pursued instead.  Luckily, m-CPBA-catalyzed 
epoxidation of the resulting diol (17) proceeded smoothly with stereoselective addition 
to the exo face of the bicycle.  Homologation of the corresponding aldehyde (18), 
followed by ozonolysis and dehydration then provide 1A as the penultimate precursor to 
tirandamycin.  Incorporation of the tetramic acid moiety was accomplished following the 
previously noted conditions shown in Scheme 2.1A. 
  
Scheme 2.4 – DeShong’s Route to 1A as Part of the Total Synthesis of () – TirA 
 
Schlessenger’s complementary approach towards the synthesis of enantiopure 
TirA requires 16 steps to access the final product via the intermediacy of acetonide 22 
(Scheme 2.5).41 Anti-selective aldol condensation of a lithium enolate derived from 
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vinylogous urethane 20 affords the desired substituted lactone,57 which upon exposure 
to Bu3SnH and AIBN, results in the removal of the stereo-defining thiomethyl adduct.  
Reductive methylation followed by consecutive removal of the pyrrolidine residue with 
m-CPBA gives the target intermediate (22).  
 
 
Scheme 2.5 – Schlessinger’s Route to 1A as Part of the Total Synthesis of () – TirA 
 
 
One highlight of Schlessinger’s synthesis is the remarkably simple yet efficient 
conversion of 22 to 23 through MeLi addition and concomitant acid catalyzed cyclization 
to furnish the bicylic ketal.  Unfortunately, attempts to oxidize 23 to aldehyde enone 27 
were not as straightforward, as treatment with chromium trioxide 3,5-dimethylpyrazole 
led to an erosion in stereochemistry in the final product.  A more indirect route from 23 
to 27 was therefore utilized instead. 
Lastly, in the first of a final series of transformations, Wittig olefination with 
(carbethoxyethylidene)triphenylphosphorane was successful in helping extend the side 
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chain towards formation of the 1-oxopentadienyl tether.  Efficient introduction of the 
epoxide was then achieved under nucleophilic conditions (t-Butyl hydroperoxide/DBU) 
to give 29, illustrating an improvement upon DeShong’s multi-step approach.42 
Following a few minor functional group interconversions, synthesis of () – TirA was 
completed as described earlier from 1A (Scheme 2.1A). 
 
2.1.3 Total Synthesis of TirC by Roush 
Many years later, the Roush group identified tirandamycin as an appropriate 
synthetic target to demonstrate the utility of their own chiral crotyl-borylating reagent in 
the context of a more complex natural product system.51,58 Specifically, Roush and co-
workers recognized the anti, anti-dipropionate stereotriad unit present in tirandamycin 
(highlighted in yellow in Scheme 2.6) as an accessible motif through mismatched 
double asymmetric -stannylcrotyl boration of intermediate 36.  The resulting stannyl 
homoallylic alcohol 37, which was obtained with >15:1 stereoselectivity, provided direct 
access to () – TirC in another six steps, thereby completing the first total synthesis of 
this particular tirandamycin congener.  Notably, MeLi addition to lactone intermediate 38 
followed by successive exposure to catalytic acid borrows from methodology previously 
reported by Schlessinger41 to provide the bicyclic ketal.   
As described in the next section, the synthesis of TirC by Roush has strongly 
influenced our work towards the engineering of a collection of enzymatic substrates 
modeled after this class of natural products.  
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Scheme 2.6 – Roush’s Route to 1C as Part of the Total Synthesis of () – TirC 
 
 
2.2 Synthesis of Tirandamycin Analogs 
2.2.1 Initial Approach Towards Synthesis of TirC Bicycle  
Encouraged by precedent in the literature on the synthesis of tirandamycin, we 
set out to create a series of tirandamycin analogs to help probe the effect of substrate 
structure on the multifunctional activity of P450s such as TamI.  Furthermore, access to 
a variety of unnatural tirandamycin analogs creates a critical opportunity to allow for the 
continued exploration of the structure-activity relationship of this important class of 
bioactive molecules.14,22,23,25,26,35  
We envisioned these analogs to closely resemble the bicycle of tirandamycin, the 
only structural feature to be oxidized by TamI as part of the tirandamycin biosynthetic 
pathway15 and a necessary structural feature influencing its pharmacological 
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activity.15,17 These analogs also required a functional handle to allow for attachment of a 
synthetic “anchor” which would facilitate binding within the enzyme active site (see 
chapter 3).  Considering that TirC is well understood to precede P450 catalyzed 
oxidative tailoring,15 our initial plan was to synthesize the bicycle of TirC with a free 
hydroxyl located off of C6 in place of the naturally occurring dienoyl side chain (51, 
Scheme 2.7).  This alcohol would serve as a point of attachment for carboxylate 
containing anchors or could otherwise be easily modified to allow for incorporation of 
other anchoring functionalities. 
 
Scheme 2.7 – Initial Approach Towards an Analog of TirC 
 
 
Our original intent was not to reinvent the synthesis of the TirC bicycle but to 
instead utilize the methods previously established by Roush51 (Scheme 2.6) to access 
analog 51 as quickly as possible.  Starting from the commercially available ester (40), 
TBDPS protection followed by DIBAL-H reduction of the resulting ester gave aldehyde 
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41 in a 73% yield over two steps. Allylboration using an in situ generated (+)-(Ipc)2 
allylborane species provided enantioenriched homoallylic alcohol 42 in moderate yield 
(51%). Acylation of 42 with methacryloyl chloride then gave ring closing metathesis 
(RCM) precursor 43 in 78% yield. 
Ring closing metathesis conditions were initially chosen according to the 
procedure by Roush et al.,51 which led to low conversions (37%).  Sparging the system 
drove the reaction forward by driving off ethylene byproduct, providing quantitative 
yields in less than two hours with decreased catalyst loading (5 mol%).  Tetrafluoro-1,4-
benzoquinone was added to prevent unwanted isomerization caused by ruthenium 
hydride species present in solution.59 
Following ring closure, lactone 44 was deprotected using TBAF in an acetic acid 
buffer to give 45 in 88% yield. Oxidation of the resulting alcohol using Dess-Martin 
periodinane (DMP) provided aldehyde 46 in 87% yield. 46 was then treated with 
methylene triphenylphosphine under suitable Wittig conditions to afford trace amounts 
of the corresponding olefin. 
 
2.2.2 Simplified Synthesis of TirC Bicycle 
At this point in our work we re-evaluated the practicality of achieving our goal of 
quickly obtaining 51 in sufficient quantities for rapid diversification and enzymatic 
screening.  Rather than repeating previous work to bring forward more material and 
carry forward our initial strategy, we recognized that this approach was not amenable to 
efficient, large-scale substrate synthesis.  By eliminating incorporation of the C17 methyl 
group, we realized that an otherwise analogous TirC analog (57) could be accessed in 6 
steps instead of 13 steps (Scheme 2.8).  Since C17 is remote from the multiple sites of 
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oxidation in the biosynthesis of tirandamycin and is instead located proximal to the point 
of anchor attachment, (a region typically not oxidized by P450s which operate via an 
anchoring type mechanism), its omittance is likely to be inconsequential in our analysis. 
 
 
Scheme 2.8 – Comparison of Synthetic Strategies Towards a TirC Analog 
 
Altering our focus towards a more simplified approach fulfills a noticeable gap in 
the literature in this area.  While prior work on the synthesis of tirandamycin is 
extensive, no methods exist for the direct access to the tirandamycin core with minimal 
synthetic manipulation.  The discovery of a more viable route towards tirandamycin 
would therefore enable more rapid pharmacological evaluation of this family of natural 
products. 
Utilization of  (4S)-(+)-4-(2-Hydroxyethyl)-2,2-dimethyl-1,3-dioxolane (52) as the 
starting material for our second generation synthesis strategically provides the C7 
stereocenter, which often is installed through more complex asymmetric methods51 
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(Scheme 2.9).  52 Is currently available for $12/g from Sigma Aldrich,60 making it a cost-
effective reagent for large-scale synthesis.   
PCC oxidation of 52 afforded the requisite aldehyde, albeit in diminished yields 
(59%) due to the volatility of 53. Adaptation of methods previously established by 
Roush, which were also utilized in our previous synthesis, then provided homoallylic 
alcohol 54 in 52% yield after being purified twice by column chromatography.  Residual 
crude product was typically set aside and purified with product mixtures from later 
reactions to isolate remaining material.  Acylation of 54 with methacryloyl chloride 
subsequently gave ester 55 in 73% yield, which was aided by the addition of DMAP to 
the reaction.   
 
Scheme 2.9 – Improved Synthesis of an Analog of TirC 
 
  
Use of the previously established RCM conditions from the original analog 
synthesis did not work well on a larger scale (> 0.8 mmol), resulting in significant dimer 
formation and incomplete conversion of starting material.  Fortunately, addition of an 
extra 5 mol% of catalyst several hours after the initial catalyst addition drove the 
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reaction to full conversion to give product 56 in near quantitative yields (98%).  Lastly, 
MeLi addition followed by tandem acetonide deprotection and cyclization produced TirC 
analog 57 in a 71% yield over the final two steps. 
 
2.2.3 Diversification of Analog Synthesis 
 
In order to further assess the impact of substrate structure on P450 activity, we 
explored our ability to use late stage chemical oxidation methods as a means towards a 
wider variety of tirandamycin analogs beyond TirC.  Gratifyingly, manganese (III) 
acetate catalyzed allylic oxidation61 of 57 provided enone 58, a TirD analog, in moderate 
yields (45%, Scheme 2.10).  Stereoselective reduction of the allylic ketone, in which the 
hydride was introduced exclusively onto the exo face, gave TirE analog 59 in one 
additional step (63% yield). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.10 – Synthesis of Additional Analogs of Tirandamycin 
 
 
 We were also pleased to find that higher oxidation analogs of tirandamycin could 
be synthesized through selection of the appropriate reaction conditions.  Although the 
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use of electrophilic oxidants such as m-CPBA were unreactive with the electron 
deficient olefin of 58, treatment with t-Butyl hydroperoxide and DBU afforded TirA 
analog 60 with good facial selectivity. 
 
2.3 Conclusions and Future Directions 
 In summary, we have reported a concise route towards the synthesis of a series 
of tirandamycin analogs which greatly improves upon the utility of previous synthetic 
approaches.  Future work will include the application of new chemical methods to afford 
key intermediates in a more novel and efficient manner.  The increased accessibility of 
this scaffold not only enables research on tirandamycin as a substrate for P450s 
(chapter 3), but opens the door for future structure-activity studies on this important 
class of biomolecules.  Results from this chapter will be published in due course. 
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CHAPTER III 
Strategies for Enabling P450 Oxidations & Applications to the Tirandamycin Core 
 
 Our initial interest in tirandamycin and the cytochrome P450 TamI stems from the 
Montgomery and Sherman groups’ long-standing history in P450 mediated biocatalysis. 
Utilization of the engineered P450 PikC has resulted in several substantial contributions 
to the field, such as the regioselective hydroxylation of macrocyclic62 and small 
molecule ring systems,63 including the tirandamycin core.  The following chapter will 
discuss our successful implementation of a substrate engineering approach64,65 with 
PikC and early work towards development of a similar strategy with TamI to address 
some of the limitations of these previous methods. 
 
3.1 Development of PikC as a General Catalyst for C-H Functionalization 
3.1.1 PikC Mediated Oxidation of Macrolide Antibiotics 
 The bacterial P450 monooxygenase PikC is responsible for the oxidative tailoring 
of the 12- and 14-membered macrolides YC-17 and narbomycin in Strep. venezuelae 
(Scheme 3.1).66 YC-17 and narbomycin are produced from variable termination of 
polyketide chain elongation intermediates in the pikromycin biosynthetic pathway, 
followed by DesVII catalyzed attachment of desosamine.67,68 Desosamine has been 
found to affect both the biological activity of macrolide antibiotics69–71 and their post-PKS 
modification72 through a unique anchoring mechanism involving the N,N-dimethylamino 
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group of the sugar.  Salt bridge interactions between the protonated dimethylamino 
group of YC-17 and narbomycin play a key role in substrate binding and catalysis with 
PikC, affording methymycin and neomethymycin in 1:1 ratio and pikromycin over 
neopikromycin in a 38:1 ratio (Scheme 3.1).  Dihydroxylated macrolide novamethymycin 
has also been isolated and characterized as a minor oxidation product of the PikC 
catalyzed reaction in Strep. venezuelae.73 
 
 
Scheme 3.1 – PikC Catalyzed Site Selective Oxidation of Macrolide Antibiotics YC-17 
and Narbomycin 
 
 
YC-17 and narbomycin are anchored in two distinct binding pockets of PikC, as 
shown by co-crystal structures of both substrates in the enzyme active site (Figure 
3.1).72 While narbomycin is anchored by salt bridge contact with Glu-85 in the exposed 
pocket, YC-17 is positioned in the buried pocket by interaction with Glu-94, bringing C10 
and C12 of the macrolactone ring within close proximity of the heme iron for 
regioselective oxidation.  Elimination of the surface exposed Asp-50 residue results in 
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the formation of a more active PikCD50N mutant by relocation of substrate to the 
catalytically productive buried site.74 
 
Figure 3.1 – Co-crystal Structure Showing Desosamine Binding Interactions of 
Narbomycin (A) and YC-17 (B) in the PikC Active Site (Hydrogen bonds are shown in 
green, salt bridges are in magenta and distances are in Angstroms)72 
  
 
The remarkable flexibility of PikC is shown through its accommodation of 
endogenous substrates of different ring sizes and functionalization patterns.  This is 
largely due to the non-specific hydrophobic interactions that bind both macrolactone 
rings in YC-17 and narbomycin,72 allowing for its potential exploitation as a biocatalyst 
for a broad range of substrate classes.  The remainder of this section will describe our 
efforts towards the use of synthetic dimethylamino anchoring groups to control the 
regioselectivity of PikC catalyzed C-H bond functionalization and access new analogs of 
tirandamycin which do not resemble readily observable biosynthetic pathway 
intermediates. 
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3.1.2 Directing Group-Controlled Regioselective Oxidation of YC-17 Analogs 
 Early studies by the Sherman and Montgomery groups validated the use of PikC 
as a general catalyst for the oxidation of a series of carbocyclic ring systems appended 
to a desosamine sugar anchor.75 While desosamine was able to promote reactivity of 
unnatural substrates with PikC, difficulties associated with the synthesis and removal of 
desosamine limit its widespread usage.  We therefore proposed a series of readily 
accessible, simplified anchoring groups that would be able to mimic the binding 
capabilities of desosamine through incorporation of various tertiary-amine-containing 
functionalities.  Appendage of these anchoring elements to the C3 hydroxyl of 10-
deoxymethynolide (10-dml) resulted in an array of YC-17 analogs which were 
subsequently reacted with an engineered, self-sufficient fusion protein,74,76 PikCD50N-
RhFRED (Table 3.1).62 Use of an ester linkage allowed for ease in attachment via DCC 
coupling and subsequent hydrolysis of the directing group following enzymatic 
oxidation. 
 In all cases, PikC oxidized YC-17 analogs to give a mixture of two products 
resulting from hydroxylation at C10 and C12, as comparable to its observed reactivity in 
nature (Scheme 3.1).  Interestingly, however, the replacement of desosamine with 
synthetic anchoring groups was found to alter the regioselectivity of the reaction based 
on the size, stereochemistry and rigidity of the chosen anchor.  Among the three YC-17 
analogs attached to linear anchors (61, 62, and 63), three-carbon propanoate derivative 
62 gave the highest conversion and selectivity of monohydroxylated products (>99%, 
1:3 in favor of C12 oxidation).  Variation in enzymatic conversion was also reflected by 
the total turnover number (TTN, moles of product/moles of enzyme) for each of these 
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substrates, which was greatest for 62 (544).  Notably, extension of the linker by one 
ethylene unit to give 63 reversed the regioselectivity from 61 and 62 in slight favor of 
allylic C10 oxygenation (1.8:1). 
 
Table 3.1 – Anchor Controlled Regioselectivity of YC-17 Analogs 
 
 
 In the case of N-methylproline derived substrates 64 and 65, expansion to a 
more structurally rigid anchor lead to improvement in conversion and TTN in 
comparison to linear anchor 61, which placed the amine a similar distance away from 
the macrolactone core.  This structural modification was also found to have a significant 
impact on the selectivity of C-H bond oxygenation, showing preferential formation for 
methymycin derivative A over neomethymycin derivative B in up to a 3:1 ratio.  The 
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greatest selectivity, however, was observed through my early work as a graduate 
student in the synthesis and attachment of various benzoic acid anchors to 10-dml.  As 
shown in table 3.1, benzylic substrates 67 and 68 showed a dramatic difference in 
regioselectivity (>20:1 and 1:4, respectively), likely due to restriction of the 
conformational freedom of the substrate within the enzyme active site.  This example of 
substrate controlled regioreversal further illustrates how simple structural changes can 
lead to substantial differences in reactivity, adding to chemists’ understanding of how 
enzymes such as PikC can be used as catalysts for the functionalization of carbon-
hydrogen bonds. 
 
3.1.3 Using PikC as a Biocatalyst for the Oxidation of the Tirandamycin Bicycle 
 
3.1.3.1 Site-Selective Oxidation of Simple Ring Systems 
 
Soon after our initial discovery of the utility of synthetic anchors, co-workers 
within the Sherman and Montgomery laboratories demonstrated their application in the 
context of unnatural substrate classes (Figure 3.2).63 ()-Menthol (69) was chosen as a 
model substrate for anchor attachment due to its availability as a single enantiomer and 
its inclusion of a range of C-H bonds of variable bond strengths. Molecular dynamics 
(MD) simulations were used to rationally design a PikC triple mutant, PikCD50ND176QE246A-
RhFRED, which led to an increase in catalytic turnover caused by a shift in equilibrium 
towards a more active protein conformation.  In addition to menthol, a variety of other 
ten carbon ring systems (70-73) were selectively oxidized by the engineered PikC triple 
mutant at sites distal to the point of attachment of the anchor, even in the presence of 
more activated C-H bonds. 
Nevertheless, despite the remarkable flexibility of PikC, its capabilities have 
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remained limited primarily to the catalysis of mono-hydroxylation reactions.  Even in the 
case of olefin-containing substrates such as 70 and 71, PikC has never before been 
shown to exhibit multifunctional behavior comparable to other P450 monooxygenases 
such as TamI, raising questions as to the factors that distinguish between the reactivity 
of these two classes of enzymes.  Given precedent for the large influence of substrate 
structure on P450 activity, it is possible that certain structural features present in the 
natural substrates of multifunctional P450s may play a role in their observed catalytic 
versatility.  Our goal was therefore to use tirandamycin, the endogenous substrate of 
the multifunctional P450 TamI, as a substrate for PikC in order to investigate its 
potential mixed function capacity. 
 
 
Figure 3.2 – Site Selective Oxidation of Small Molecule Ring Systems with 
PikCD50ND176QE246A-RhFRED (Numbers in parentheses are TTN for given substrate) 
 
Prior to the synthesis of a series of tirandamycin analogs (section 2.2), 1-
adamantanemethanol was used as a model to test the feasibility of the tirandamycin 
bicycle to serve as a substrate for PikC (Table 3.2). In spite of its relative promiscuity, 
certain substrates are incompatible with PikC due to size and structural restraints.75 
Although it is not inconceivable that the tirandamycin bicycle would serve as a 
competent scaffold, this is difficult to predict without time-intensive computational 
modeling efforts.  As an alternative, we decided to attach 1-adamantanemethanol to a 
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variety of PikC anchors, including more recently developed 1,4- and 1,5-triazole 
anchors (79 and 80) which were assembled from the corresponding azido acid and 
dimethyl amino containing alkyne.77 While not a perfect model, both adamantane and 
the tirandamycin bicycle share a related skeletal framework (highlighted in blue in Table 
3.2), which should be accommodated similarly within the PikC active site.  Gratifyingly, 
modest to high conversions of adamantane derivatives with a range of linear and aryl 
anchors confirmed that the time intensive synthesis of the tirandamycin bicycle 
remained a worthwhile endeavor. 
 
 
Table 3.2 – Enzymatic Oxidation of 1-Adamantanemethanol Derivatives by 
PikCD50ND176QE246A-RhFRED 
 
 
3.1.3.2 Enzymatic Oxidation of Tirandamycin Analogs with PikC 
 
TirC analogs were synthesized as shown in Scheme 2.9 and attached to a 
collection of well-established PikC anchors, including benzylic amines, long and short 
chain linear anchors, nitrogen containing heterocycles, and 1,4-triazoles possessing 
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ortho-, meta-, and para-substituted benzene spacers (Figure 3.3).  Compounds 81, 82, 
84, 85, and 86 were first synthesized and reacted with two different PikC mutants which 
were utilized in previous studies62,63,77 (PikCD50N-RhFRED and PikCD50ND176QE246A-
RhFRED).  Not surprisingly, increased conversions were observed for substrates 81, 
82, and 84 with the catalytically superior PikC triple mutant.  Enzymatic reactions with 
remaining substrates (83, 87, 88, and 89) were therefore only run using 
PikCD50ND176QE246A-RhFRED alongside a positive control reaction with ()-menthol 
substrate 69.  Enzymatic conversions were determined from integration of the extracted 
ion chromatograms of LCMS traces, assuming equal ionization efficiencies of the 
starting material and products. 
The lack of product formation observed for 85 and 86 can be rationalized through 
an observed lack of stability of particular tirandamycin analogs.  85 and 86 readily 
hydrolyzed in the enzyme buffer solution, as evidenced by lack of a significant M+H 
peak in the total ion chromatogram of these reaction mixtures.  In addition, these 
compounds are not bench stable for extended periods of time (2 months or less).  1,4- 
and 1,5-triazole anchors are even less stable when attached to the tirandamycin bicycle 
(not shown); while the 1,5-triazole linked compound decomposes within a couple weeks 
of bench top storage, the 1,4-triazole anchor hydrolyzes upon standing within a few 
days. 
 
 
 47 
 
 
Figure 3.3 – Reaction of TirC Analogs with PikCD50N-RhFRED and PikCD50ND176QE246A-
RhFRED  
 
 Although enzymatic conversions to mono-oxidized product were low in 
comparison to former experiments with YC-17 analogs,62 in certain cases, attachment of 
structurally rigid anchors such as m-benzylic amine 82 gave yields which were similar to 
those previously obtained for small molecule ring systems.63 Meta-substituted arene 
spacers (82 and 88) out performed their para and ortho substituted counterparts (81, 
83, 87 and 89).  For example, m-aryl anchor 82 resulted in 25% conversion to M+H+16 
as opposed to 1,4- and 1,2-substituted benzylic amines, which gave 13 and 3% 
conversion, respectively.  LCMS traces typically showed conversion to at least one 
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major product, however, in most situations, a minimum of three minor mono-oxygenated 
products was also observed. 
 Fortunately, we found the selectivity and yield of meta-functionalized benzylic 
amine 82 to be sufficient to isolate and characterize two of the major reaction products 
(90 and 91) from a preparative scale reaction mixture (Figure 3.4A).  While these two 
products were not effectively resolved in our initial LCMS chromatogram (both products 
co-eluted as part of first large orange peak in Figure 3.4B), we were happy to discover 
that both compounds were separable by reverse phase preparative HPLC.  Oxidation 
occurred at the most electronically activated positions within the bicyclic ring system to 
give allylic hydroxylation at the C18 methyl (90) and C10 methylene (91).  Notably, 91 
was determined by 2D NOESY experiments to be the epimer of TirE analog 59 
(Scheme 2.10), possessing the opposite C10 stereochemistry of what is obtained in the 
first step of the TamI-TamL oxidative cascade (Scheme 1.6).  90, on the other hand, 
represents a new oxidation product that is structurally unrelated to any previously 
isolated biosynthetic intermediates.  90 is only the second reported example of primary 
C-H bond oxidation catalyzed by PikC, with (+)--terpineol derivative 70 being the 
first.63 
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Figure 3.4 – Characterization of Major Oxidation Products from Reaction of a TirC 
Analog with PikCD50ND176QE246A-RhFRED 
  
We also sought to examine higher oxidation state tirandamycin analogs (Scheme 
2.10) as substrates in anticipation that these structures, which mimic late-stage 
biosynthetic pathway intermediates, could potentially influence unique reactivity within 
PikC.  In particular, we were especially interested in trying to replicate the TamI-
catalyzed epoxidation of TirD with TirD analog 58 in order to expand the functional 
capabilities of the PikC enzyme. 
To test the feasibility of our hypothesis, allylic ketone 58 was attached to 4-
((dimethylamino)methyl)benzoic acid under the assumption that this anchor would 
provide similar conversions as previously shown with TirC analog 82 (Figure 3.3).  18% 
of this resulting material (92) was oxidized to two products with a desired mass of 
M+H+16 when subjected to PikCD50ND176QE246A-RhFRED (Figure 3.5A). (Note that both 
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products co-eluted on the analytical scale LCMS trace as shown in Figure 3.5B.)  This is 
different from other PikC catalyzed reactions with TirC analogs, which usually showed 
conversions to 4 or more different mono-oxidized products.  
 Unfortunately, less than a gram of each product was obtained from preparative 
scale reaction mixtures, making it impossible to fully characterize the isolated material 
by 2D NMR.  Interestingly, the 1H NMR of one product lacked the diagnostic singlet 
corresponding to the C11 vinyl proton around 6.2 ppm; however, neither proton NMR 
spectrum matched that of an epoxidized authentic standard.  One alternative 
explanation could be formation of the exocyclic epoxide (as found in streptolydigin) 
through C18 hydroxylation followed by Michael addition to the neighboring olefin, 
although this has yet to be confirmed through future studies. 
 
Figure 3.5 – Progress Towards Characterization of Major Oxidation Products from 
Reaction of a TirD Analog with PikCD50ND176QE246A-RhFRED 
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3.2 Preliminary Work Towards the Use of TamI as a Novel, Multifunctional 
Biocatalyst 
 
 A secondary and perhaps easier approach to developing a general, mixed-
function P450 biocatalyst would involve exploiting the versatile activity of TamI using 
substrate and protein engineering strategies similar to those previously utilized with 
PikC.  Nonetheless, several potential limitations could hinder progress towards this 
goal, namely, unfamiliarity with the native binding mechanism and substrate promiscuity 
of TamI.  In other words, if TamI does not anchor tirandamycin through several key-
binding interactions but instead is highly specialized towards the catalysis of its 
endogenous substrate, this type of strategy will not be successful. 
During the screening of tirandamycin analogs with PikC all substrates were also 
reacted with the TamI fusion protein, TamI-RhFRED (Figure 3.6).  Not surprisingly, the 
majority of compounds did not show any conversion to oxidized product.  However, 
meta-substituted benzylic amine 82 did show a minor amount of reactivity, indicating  
that unnatural substrates can be accommodated within the TamI active site. 
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Figure 3.6 – Reaction of Tirandamycin Analogs with TamI-RhFRED 
 
3.2.1 Insights into Substrate Binding and Anchoring Mechanism  
Preliminary enzymatic experiments with late-stage intermediates from the total 
synthesis of TirC by Roush et al.51 provided early evidence that the tetramic acid moiety 
may be important for catalysis with TamI (Scheme 3.2).  These compounds, which were 
generously given to us by the Roush lab, were tested as substrates for TamI-RhFRED 
in order to probe the structural requirements necessary for expanding the substrate 
scope of TamI.  Interestingly, only the TirC control was oxidized in vitro, while 
tirandamycin derivatives that lacked the tetramic moiety (39 and 1C) showed no 
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reactivity.  This potentially suggests that, similar to desosamine,72 the tetramic acid of 
tirandamycin serves as an anchor which is responsible for orienting and binding 
substrates in TamI.  Furthermore, the lack of reactivity of DMB-protected tetramic acid 
94 could indicate that the N-H bond of the 2,4-pyrrolidinedione ring system forms a 
necessary electrostatic interaction with catalytic residues in the binding pocket of TamI; 
however, it is more likely that the benzyl protecting group is too sterically encumbering 
to be accepted into the enzyme active site. 
 
Scheme 3.2 – Reaction of Late-Stage Roush Intermediates with TamI-RhFRED 
 
Obtaining crystallographic information on the protein structure and binding 
mechanism of TamI has long eluded our groups’ research efforts.  Original attempts at 
crystallizing TamI resulted in a crystallographic dimer structure via an engineered N-
terminal overhang coding for a His-tag40 (Figure 3.7A).  Relocation of the His-tag to the 
C-terminus of the protein had no positive effect on crystallization. 
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Figure 3.7 – TamI Crystal Structure A: TamI Crystallographic Dimer (Unpublished work 
by Dr. Larissa Podust) B-D: TirC Bound Structure of TamI (Unpublished work by Dr. 
Sean Newmister) 
 
Members of our research team hypothesized that cleaving the N-terminal His-tag 
may free access to the active site.  Consequently, TamI was engineered with a 
cleavable N terminus leading to successful co-crystallization with TirC.  The resolved 
structure reveals several valuable insights into the origin of binding and selectivity in this 
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multifunctional P450.  As expected, the orientation of the tirandamycin bicycle matches 
its observed reactivity, with the C10 allylic methylene of TirC situated 4.1 Å away from 
the iron heme center (Figure 3.7B).  Furthermore, non-specific stabilizing interactions 
allow for flexibility in size and orientation of the bicyclic ketal.  This aligns well with the 
proposed biosynthetic pathway of tirandamycin, which requires the repositioning of the 
bicycle in order to facilitate sequential oxidation.   
The tetramic acid moiety is much more tightly packed in the TamI active site and 
seems to be held in place through potential hydrogen bonding interactions with several 
amino acid residues, including Leu-399, Ser-397, Thr-398, and Pro-43 (Figure 3.7C/D).  
While the backbone of Leu-399 and alcohol side chain of Ser-397 appear to form a tight 
contact with the C1 enol of tirandamycin, the backbone of Thr-398 is positioned to 
engage in similar interactions with the C1 enol and the C2’ carbonyl of the tetramic acid.  
The tetramate nitrogen was also identified to potentially aid in substrate binding through 
association with the backbone of Pro-43.  These crystallographic insights, in 
combination with preliminary computational docking efforts with other tirandamycin 
congeners, further suggest that an anchoring mechanism may be operational. 
 
3.2.2 Work Towards the Synthesis and Design of TamI Anchors 
As mentioned previously, tirandamycin analogs attached to PikC anchors 
showed minimal to no reactivity with TamI-RhFRED (Figure 3.6).  Motivated by recent 
findings from the TamI crystal structure, we were interested in seeing if incorporation of 
a tetramic acid moiety would improve enzymatic conversions and validate our 
hypothesis in support of an anchoring mechanism.  TirC analog 96 was synthesized 
through DMP oxidation of bicycle 57, followed by Horner-Wadsworth Emmons 
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Olefination with phosphonate tetramic acid 3 (Scheme 2.1A).  Deprotection of the DMB 
group, however, proved challenging (Table 3.3).  A variety of different reaction 
conditions were screened following previously reported procedures.44,51,52 In all cases, 
decomposition of the starting material was observed by 1H NMR with no evidence of 
conversion to deprotected product.  Decomposition of the unanchored bicycle was also 
observed after stirring in TFA/DCM at 0oC for 5 minutes.  In the future, more labile 
protecting groups could be used to remove the amide substituent under milder 
conditions. 
 
 
Table 3.3 – Attempts at Deprotection of DMB Group 
 New insights into potential binding interactions in TamI have inspired the design 
of more compatible synthetic anchors, which incorporate key structural features (e.g. 
primary amines, amides, and 1,3-dicarbonyls) predicted to be important for substrate 
binding (Figure 3.8).  Anchors will be synthesized either through simple modifications of 
PikC anchors (98, 99) or derivatization of other readily accessible core scaffolds, such 
as cyclic ureas. 
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Figure 3.8 – Design of Synthetic TamI Anchors 
 
3.3 Conclusions and Future Directions  
Overall, the work described in this chapter highlights the development of 
cytochrome P450 enzymes as site-selective biocatalysts for multi-functional C-H 
oxidation.  Tirandamycin analogs were effectively oxidized by PikC to afford novel 
oxidation scaffolds which are not readily accessible through natural product pathways, 
thereby illustrating another unnatural substrate class for this versatile P450.  
Furthermore, TamI has shown early promise to be used as a complementary P450 for 
multifunctional C-H oxidation.  While the complex factors governing mixed-function 
behavior in P450s are still not yet fully understood, future work involving a combination 
of computationally guided substrate and protein engineering efforts will lead to 
increased knowledge in this area.  This will include both rational mutagenesis and 
synthetic manipulation of tirandamycin and its analogs to elucidate key structural 
features important for binding and activity, making further progress towards the use of 
enzymes as a tool for the diversification of a broad range of target molecules. 
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CHAPTER IV 
Investigating the Benefits of a R1/PUI Laboratory Exchange Program Related to 
Graduate and Undergraduate Student Learning and Professional Development 
 
 
 
4.1 Introduction 
  While the synthetic studies presented in chapters 1-3 of this thesis have played 
a major role in my graduate career, I have also had the opportunity to design and 
implement an educational research project which has focused on learning in the 
laboratory environment.  Specifically, this project involves a two-part student exchange 
between the Montgomery* laboratory and an undergraduate lab at Hope College in 
Holland, MI that was established in order to help provide exchange program participants 
with valuable professional development experiences such as working in or managing a 
research laboratory. 
 The idea for a laboratory exchange program was originally proposed as an 
initiative to help supplement the career development training offered to graduate 
students through the University of Michigan chemistry department.  A long-standing 
challenge in the education of future faculty members in the sciences is that professional 
preparation often focuses heavily on students’ training as scientists at the expense of 
their training as educators.  As Coppola78 argues: 
                                                        
*Unless otherwise noted, permission was given to disclose participants’ identity. 
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[T]he extent of professional readiness required for discovery research…should 
be, if not must be, broadened to include the full array of responsibilities and 
obligations for a member of a faculty on the first day of one’s independent 
career…If we trained physicians the way we train professors, we would never let 
them see a patient or use a stethoscope before they stepped into their first 
practice. 
 
Arguably, major research institutions such as the University of Michigan are 
better positioned to provide support for students looking to pursue careers in academia 
at an R1 research university79 since faculty have direct personal experience establishing 
themselves in this type of setting.  However, in the field of chemistry for example, only 
190 out of 5000 colleges and universities grant doctorate degrees, with almost 50% of 
Ph.D. students enrolled at only 30 of these schools.79,80 It is therefore unlikely that 
prospective chemistry professors will end up teaching in an environment similar to their 
graduate institution. 
Providing assistance to graduate students looking to teach at primarily 
undergraduate institutions (PUIs) is not straightforward either.  Although departmental 
seminars and workshops sponsored by internal professional development 
infrastructure78 can help bridge the gap, this does not serve as a sufficient replacement 
for hands-on, in-person experience working in the unique atmosphere of a private, 
liberal arts institution.  Furthermore, even students who may be familiar with the PUI 
culture from their undergraduate studies likely were not focused on learning how to 
serve as a faculty member during their time there.  Creating an opportunity for graduate 
students to work alongside teachers and students at a PUI for an extended period of 
time during their Ph.D. candidacy would therefore be beneficial to students, especially 
before they commit to this particular career path. 
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With respect to undergraduates, there are a wide variety of exchange program 
opportunities available to undergraduate students looking for discipline-specific 
research experiences in science, technology, engineering and math (STEM).  The 
National Science Foundation’s (NSF) Research Experiences for Undergraduates (REU) 
program, for example, began in 1987 in an effort to encourage undergraduate 
engagement in authentic research practice and continuing education into graduate 
school.81 Typically, REU students are given a stipend to travel to a host institution and 
work on an NSF-funded research project under the guidance of faculty and graduate 
student mentors.  Similar study abroad opportunities are offered through the RISE 
(Research Internships in Science and Engineering) Program, Trans-Atlantic Science 
Student Exchange Program (TASSEP), and the Fulbright Program, among others.82   
The benefits of undergraduate research are well studied in the literature, having 
a strong influence on students’ future career decisions, scientific understanding, and 
research and communication skills.81,83–86 However, one-time, 10-week exchange 
experiences, such as the ones supported through the REU program, make it difficult for 
students to form long-lasting, sustainable interactions with their assigned mentors, given 
that these programs are relatively brief and have no mechanism in place for continued 
communication beyond the 10-week period.  Work by Thiry and Laursen87,88 suggests 
that this is an important factor to consider, showing a significant correlation between the 
amount of time spent with research mentors (typically identified as either graduate 
students, postdoctoral researchers, or the principle investigator of the laboratory) and 
students’ overall satisfaction and intellectual gains.  Furthermore, Sadler et al.89 noticed 
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a similar correlation between the length of research experiences and participant 
learning outcomes. 
Prior to starting this work, the Montgomery lab had been fortunate to establish a 
relationship with Professor Jeff Johnson’s laboratory at Hope College through mutual 
research interests, relative geographic proximity, and an overlap in student workers (i.e. 
students who graduated from the Johnson lab and then worked as graduate students in 
the Montgomery lab).  Hope College is a Christian, liberal arts college located in 
Holland, MI with a student body of approximately 3,000 undergraduates and an 
internationally recognized chemistry department.90 In the ten years that Dr. Johnson has 
been a professor at Hope College he has mentored over fifty undergraduate and visiting 
high school students, many of whom are co-authors on high-impact publications 
stemming from their research accomplishments in his lab.91,92 His professional 
accomplishments in teaching and research have been recognized through his receipt of 
numerous awards, including the prestigious Henry Dreyfus Teacher-Scholar Award in 
2015. 
The objective for initiating an R1/PUI student exchange was to create a program 
that would meet the unique needs of both graduate and undergraduate students while 
simultaneously reinforcing continual interaction between our two research groups.  We 
envisioned that this exchange program would provide invaluable career development 
training for graduate students by allowing them to learn directly from an undergraduate 
instructor about how to manage the different responsibilities associated with a career at 
a PUI, such as running an undergraduate research laboratory.  Similarly, the 
undergraduate student participant would hopefully gain a more informed perspective on 
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graduate school at an R1 institution and develop important research and critical thinking 
skills. 
We purposefully chose to organize this exchange sequentially over the course of 
two summers, with a graduate student visiting Hope College for four weeks the first 
summer and then mentoring a member of the Johnson lab at the University of Michigan 
for 10 weeks the following year.  By extending the exchange program over a two-year 
period and providing the graduate student the chance to observe effective laboratory 
teaching practices prior to mentoring the undergraduate in the R1 research setting, we 
hoped to improve both the quality and quantity of student-mentor interactions.  
Furthermore, we believed that giving the graduate student first-hand perspective on the 
undergraduate student’s background knowledge and experiences prior to working with 
him or her in the Montgomery lab would contribute to an overall more effective learning 
experience for both parties involved. 
In the summer of 2015 I was fortunate enough to be given the opportunity to 
participate in the first iteration of the Montgomery/Johnson lab exchange and work 
alongside Stanna Dorn, a Hope College undergraduate going into her junior year as a 
chemistry major at the time.  The remainder of this chapter will focus on describing what 
we learned from this experience, which was analyzed as part of a case study in order to 
investigate whether or not our design of this exchange program had the impact we 
intended.  Specifically, the research questions we were interested in answering were: 
What can a graduate student and a PUI undergraduate learn from visiting each other’s 
laboratories that is beneficial to their professional development?  How did this learning 
occur? 
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4.2 Background 
 Laboratory learning is well characterized by situated learning theory, a 
perspective first introduced by Lave and Wenger93,94 which describes learning as being 
situated in specific communities of practice, and mediated by experiences, practices, 
norms, tools, and relationships with others.  In this sense, learning is situated within the 
same context in which it is applied, as is embodied by apprentices in various 
conventional trades (e.g. tailors, midwives).  In other words, instead of potentially 
passive learning from a textbook or lecture, learning occurs through ongoing 
engagement with a group of people working and learning together towards a common 
interest.  “Newcomers” to this community learn through “legitimate peripheral 
participation,” completing tasks that are necessary, although not central, to the overall 
functioning of the community.  For example, Lave95 describes how apprentice Liberian 
tailors must start by ironing garments before learning how to sew.  Furthermore, gradual 
socialization into a community of practice is not only associated with mastery of a 
particular skill-set, but a change in identity as a master practitioner of the trade. 
 Mentoring is a key component of any apprenticeship.  Direction and support from 
a mentor help an apprentice advance their learning beyond their independent 
capabilities, a concept well explained by Vygotsky’s zone of proximal development 
(ZPD).96 According to Vygotsky, the ZPD is the difference between what a learner can 
do independently and what a learner can do with the help of a more experienced other. 
This helps the learner work towards greater autonomy and proficiency in a certain area, 
until he or she no longer needs the support provided by others but can instead serve as 
an advisor to newer members of the community. 
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Scaffolding can be an important set of supports to help learners make progress 
toward solving a problem or completing a task which would otherwise be outside the 
limits of their current potential.97 An early example of scaffolding as described by 
Jerome Bruner98 includes the use of picture book reading by parents to help young 
children acquire meaning when learning how to speak.  In general, scaffolding occurs 
by 1) initially reducing the difficulty of the task at hand, 2) focusing the learner’s 
attention on relevant details, and 3) modeling desired behaviors towards completion of a 
task.  The scaffold is then gradually removed as the learner becomes more 
knowledgeable.   
 Academic research laboratories are an example site for modern-day 
apprenticeships.  The training of young research scientists is not unlike that of 
traditional apprentices; just as Liberian tailors99 must learn through observation of their 
elders and through the completion of tasks that are legitimate and peripheral to the 
practice of tailoring, new students in a research lab must also learn basic skills by 
working closely under the supervision of a more experienced mentor.  This typically 
involves novice student researchers repeating known or simple experimental 
procedures before starting to work independently on their own original research 
projects. 
Several studies have analyzed how learning occurs through secondary and post-
secondary research apprenticeships.88,89,100–105 However, to the best of our knowledge, 
similar research has not been conducted on laboratory exchange programs in which 
members of two or more participating research groups work in each other’s laboratories 
for an extended period of time.  As noted by Lemke,106 time is an important factor to pay 
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attention to when studying learning, especially when considering issues of identity 
development, which take place over longer timescales.  By focusing on participants’ 
personal growth over the course of two separate summers, we argue that more long-
term learning trajectories will become increasingly visible.  Furthermore, as mentioned 
earlier, the collaborative nature of an exchange program creates the opportunity for 
extended interaction with mentors, which may confer additional learning benefits.87,88 
Therefore, studying exchange programs as research apprenticeships, and thus, sites of 
science-related learning and identity formation, is an important contribution to the 
literature.  We hypothesize that by immersing oneself in a different, albeit related, 
community of practice, exchange program participants have access to learning 
opportunities that they would not ordinarily have. 
 
4.3 Methods and Analysis 
 Our research was conducted as a two-part case study to coincide with both 
stages of implementation of the exchange program, i.e., my visitation to Hope College in 
June 2015 and Stanna’s visit to the University of Michigan the following summer.  Case 
studies provide an in-depth investigation of a bounded system (e.g. people, event 
activity, program) that is delineated in terms of time and space in order to provide a 
finite limit to data collection and analysis.107,108 In this particular instance, the focus of 
our case study was bounded by the 14-week time period of the Montgomery/Johnson 
lab exchange program and concentrated on exploring the learning benefits of only its 
main participants (myself and Stanna).  Despite the importance of defining boundaries 
around the object of study, often times in case studies the boundaries between 
phenomenon and context are not obvious.109 This drastically opposes most 
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experimental studies, in which the setting is typically controlled for in order to study only 
a handful of variables.  Case studies, on the other hand, frequently involve a large 
number of interconnected variables which are evaluated through the triangulation of 
multiple sources of evidence.  In this study, extensive collection and analysis of 
interview data, field notes and reflections allowed for a more thorough understanding of 
specific details and learning processes that would not otherwise be captured through 
quantitative methods. 
Since the sample size of a case study is so small (n =1), our findings were not 
intended to give generalizable results that would necessarily apply in an investigation of 
other exchange programs, but instead were intended to contribute to the literature on 
how learning occurs in these types of settings.  We anticipated that these results would 
not only be useful for re-design of future iterations of the Montgomery/Johnson 
exchange, but also hoped that positive outlooks from this study would inspire similar 
initiatives between other laboratories and provide support for future funding of these 
opportunities. 
During my time at Hope College I conducted a series of four different semi-
structured interviews with select members of the Johnson laboratory, including Dr. 
Johnson himself.  The semi-structured110,111 nature of the interviews ensured 
conversations stayed focused and consistent, while still providing flexibility for follow-up 
questions and elaboration of student responses where necessary.  Interview questions 
were pre-written before the start of the exchange and centered on topics such as the 
group dynamic, Professor Johnson’s mentoring style, and students’ experiences 
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working and learning in the laboratory.  All of the interview questions used in this study 
are included in chapter 5 of this thesis (supporting information). 
Students who were interviewed were selected from a variety of backgrounds and 
expertise, taking into consideration differences in grade level, gender, and years of 
research experience.  Pseudonyms are used to protect the identity of these students, 
with the exception of Stanna, who gave us permission to use her real name in order to 
acknowledge her significant contributions towards both this project and other aspects of 
this dissertation research, which were previously disclosed. 
As summarized in table 4.1, the four students I interviewed were Stanna, Karen, 
Lucy, and Ben. Stanna and Karen agreed to be interviewed together as part of a small 
focus group since they were close friends and felt comfortable speaking candidly in front 
of one another.  At the time of the interview, Lucy was going into her junior year as a 
chemistry major at Hope College and was the most senior member of the Johnson lab 
due to her participation in the Research Experience Across Cultures at Hope (REACH) 
program, which allowed her to work in Professor Johnson’s lab for two summers as a 
high school student.  Ben, Stanna and Karen were all in their first year working in the 
Johnson lab, however Stanna had experience working in a different laboratory the 
previous summer. Both Stanna and Karen were soon-to-be juniors whereas Ben was 
going to be a senior at the time that this research was conducted. 
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Table 4.1 – Johnson Lab Interview Participants 
 While interview data served as our primary source of data from this portion of our 
case study, field notes111–113 were also recorded to document the 4-week visitation.   
These consisted of observations of lab members’ interactions, summaries of my daily 
experiences and conversations with others, and personal learning reflections in 
response to these occurrences.  These insights were also incorporated into our analysis 
of the exchange program. 
Interviews were used to more closely reveal Stanna’s perception of the exchange 
program throughout her time in the Montgomery lab.  Interviews were conducted at the 
beginning, middle, and end of the visitation at one, five, and ten weeks, respectively, 
and focused on topics such as expectations of the exchange program, difficulties and 
struggles that occurred along the way, and perceived personal and professional 
learning outcomes.  A brief follow-up interview was also conducted in order to gauge the 
impact of the experience two months following Stanna’s return to Hope. 
All interviews used throughout the study were recorded and later transcribed.  
Emergent themes were then identified across the entire data corpus, including 
interviews from both segments of the exchange program and accompanying field notes.  
Codes were limited to themes that were prevalent across the entire data set, provided 
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bearing on the research questions, and were well aligned with outcomes which were 
previously identified in the research apprenticeship literature.88,89,100–105 
 
4.4 Results and Discussion 
4.4.1 Hope College Visitation 
Early in June 2015 I came to the Johnson laboratory interested in learning what 
factors make Dr. Johnson’s research program so “successful,” as evidenced by: 1) the 
large number of publications Professor Johnson has co-authored in the short amount of 
time since starting his independent career, and 2) the far-reaching personal impact he 
has on his students, seen through the fond memories they share long after graduating.  
I hoped that by studying first hand how the Johnson lab functions, this experience would 
provide me with valuable insights that would someday be useful when starting my own 
research laboratory.   
Most of the lab’s accomplishments can be linked in some way to its purposeful 
structuring into a community of practice.93,94 Despite being comprised entirely of 
undergraduate and visiting high school students, the Johnson lab functions much the 
same as a typical academic laboratory at an R1 institution, with more expert students 
serving as mentors for new lab members.  This structure allows for the lab to overcome 
critical limitations that often plague PUI laboratories, such as lack of dedicated research 
time and student experience.  By intentionally assigning certain students to leadership 
positions, Professor Johnson is able to manage a larger number of students, while 
staying focused on matters that are more important for the overall organization and 
success of the laboratory.  As he describes: 
I put a lot of emphasis on when students are returning that they take leadership 
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roles, whether official or unofficial, to kind of mentor new students, and I still keep 
an eye on students and what they’re doing, of course, cause you don’t want 
people teaching the wrong thing, but to try to get that sort of system going, and 
have a “critical mass” of returning students each year, then it definitely takes a lot 
of the day-to-day, “Ok, now where do I find the test tubes?” or “Where do I find 
the solvent?” and pushes that off on other students who can handle that sort of 
thing. 
 
Lab members support each other in many ways other than just helping find test 
tubes and solvent, however.  Karen, for example, commented on how she felt the 
relatively large size of the Johnson lab leads to the exchange of multiple, diverse 
viewpoints which would not otherwise be visible if students worked independently of one 
another.  This in many ways is reminiscent of Vygotsky’s zone of proximal development, 
in which learners’ move beyond their normal capabilities through the assistance of 
others:96 
I think that because he has so many of us, it means that you get more 
perspectives than you would otherwise. So I know that sometimes we’ll be sitting 
and someone will suggest something that I never would have thought of, and 
then someone else will suggest something else that no one else in the group 
ever would have thought of, and it’s just we all have different experiences. And to 
a degree, a lot of our chemistry experience is similar but everyone thinks in 
different ways. So by making us all part of it, he’s getting all those different 
perspectives. And it also means that we can just push through [research]…. So I 
think some of it is just having that many people speeds up the [research] 
process. 
 
Others outside of the laboratory seemed to recognize the benefits of this shared 
sense of community as well.  Stanna, for example, recalled how observing Johnson lab 
members’ interactions while working in a different lab her first summer at Hope made 
her want to be included: 
Last summer I got to watch the whole Johnson group dynamic from the outside 
and I saw how tight-knit everybody was and I was like, “Wow, I would really love 
to be a part of a community and I feel like I would benefit from that kind of 
community.” 
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 The research apprenticeship literature has identified a number of personal and 
professional gains associated with newcomers’ socialization into a research community, 
including increased understanding about the nature of science (NOS), intellectual 
growth, and impact on participants’ career aspirations.89 Similarly, we discovered 
several specific elements from our data that are important components of the Johnson 
lab’s community of practice: the development of trust among lab members, and an 
increase in students’ confidence, independence, and enjoyment in engaging in 
authentic scientific research (Figure 4.1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 – Elements Linked to Johnson Lab Group Structure as a Community of 
Practice 
 
As shown in Figure 4.1, we not only noticed a relationship between each of these 
elements and group structure, but also an interdependency of elements on one another.  
For example, as students gained more autonomy in designing experiments and 
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troubleshooting problems, they also became more confident in their abilities, something 
that Stanna, Lucy and Ben all said they struggled with in the beginning.  Establishing a 
foundation of trust in the lab was also important in helping students feel more 
comfortable to take intellectual risks.  The independence that Dr. Johnson gives his 
students is taken as a sign of his trust in them, which in turn helps them to grow as 
scientists.  As Ben stated: 
The second time I would be doing [a procedure] all by myself because I feel like 
he trusts us that giving us instructions and also combining our lab mates’ 
knowledge, we can reproduce results the second time from what he told us and 
what we observe[d]…I just feel like we are so self-sufficient and able to do so 
many things because [Dr. Johnson] trusts us with our abilities and in return we 
don’t want to squander his trust. 
 
Almost all students mentioned the importance of finding enjoyment and 
happiness in their work, particularly in their interactions with others. This was also 
consistently apparent from observations of the students, who took time during lunch to 
go outside and play lawn games, maintained an on-going game of chemistry Scrabble, 
and organized an entire dress up week where lab members came to work in themed 
costumes.  The enjoyment of these social practices is a cherished tradition shared by 
members of the Johnson lab.  While these activities may seem somewhat counter-
productive and distracting, these customs create a more comfortable and welcoming 
atmosphere for new students and lead to the development of trusting, collegial 
relationships among lab members.  Furthermore, Dr. Johnson also attributes this 
laidback behavior as a contributing factor in his students’ success.  As he mentioned in 
his interview with me, “These kids are far more productive because they’re goofing off 
all the time than some other labs in the area where they’re kind of under the thumb.” 
 74 
Table 4.2 provides additional empirical support for the identification of these four 
major elements (confidence, independence, trust, and fun/happiness) by interview 
participants.  Although the specific learning gains of these individuals were not explicitly 
studied in this context, these attributes are unequivocally linked to several important 
aspects of learning, as described in the National Research Council’s (NRC’s) How 
People Learn.114 For example, students reported increases in confidence through 
receiving peer feedback, and developed a sense of comfort in asking questions and 
taking intellectual risks.  These elements are well supported through community-based 
teaching practices,94 which cannot only lead to an increase in cognitive development, 
but can help challenge students’ own misconceptions about how they learn.115 
 
Table 4.2 – Descriptions of Confidence, Independence, Trust and Fun / Happiness from 
Student Interviews 
   
In order to better understand my own personal impact from the exchange, we 
turned to analysis of field notes and personal reflections which were maintained over 
the course of the 4-week visitation experience.  These data focused on many of the 
same emergent themes which were identified through participant interviews, including 
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group size/structure, independence, and fun/happiness.  Some of these observations 
focused on similarities and differences I noticed between the Johnson laboratory and 
my own prior research experiences.  In many ways the Johnson lab reminded me more 
of the Montgomery lab than the PUI lab I worked in as an undergraduate, which 
consisted of only 2 or 3 students and was much more closely supervised.  As 
mentioned earlier, the Johnson lab seemed to model an R1 research group through its 
size, organization, and established practices.  For instance, students functioned 
relatively independent of Dr. Johnson, as shown by their sustained productivity in his 
absence.  Instead of relying on Dr. Johnson for assistance or approval, students’ 
arrangement into different project-focused sub-groups provided support for members to 
work together towards achieving research goals, which were then presented and 
discussed with the entire lab during weekly group meetings.   
More importantly, I learned that students appreciated this group structure and 
preferred being given the opportunity to work independently and learn from their own 
mistakes.  This immediately impacted how I interacted with others in the Johnson 
laboratory, especially a high school student who I was in charge of mentoring at the 
time.  Instead of intently watching over the student or repeatedly telling him what to do 
(as I would have previously done), I gave him the freedom to learn through guided 
discovery,116 still providing assistance and teaching him the appropriate research and 
safety skills when necessary.  This carried over into how I mentored Stanna the 
following summer in the Montgomery laboratory, allowing her to quickly grow into a 
more independent researcher (see section 4.4.2 below). 
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The widespread benefits of fostering enjoyment within the laboratory community 
also became much more apparent to me after working in the Johnson group.  Beyond 
promoting happiness, I realized that encouraging students to have fun leads to an 
increase in trust among lab members and inspires the confidence to take risks.  As I 
wrote on one of my last days at Hope, “Doing chemistry research doesn’t have to be a 
stressful, intense experience but instead should be FUN, especially when teaching and 
learning at this level.”  This is a concept I have since tried to incorporate in my own 
teaching practices and hope to one-day apply as a foundation for my future research 
group. 
My personal learning through this experience was influenced by a variety of 
factors, including my own engagement in the Johnson lab community of practice.93,94 
Just as Johnson lab members were informed by the customs and routines shared by 
others in the community, I too learned by working in the laboratory as a part of their 
group.  This enabled me to acquire information that I ordinarily wouldn’t have through 
outside conversations with lab members; instead, developing a relationship with 
students in the lab allowed them to trust me with valuable information and observe 
intimate details of their day-to-day lives.  Furthermore, recording my thoughts and 
experiences through periodic reflection employed meta-cognitive learning strategies114 
which led me to actively consider my thinking and better recall these ideas at a later 
date. 
4.4.2 University of Michigan Visitation 
 
 Stanna’s 10-week visit to the Montgomery lab can similarly be characterized as a 
research apprenticeship.  Despite her previous research experience, Stanna’s relative 
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unfamiliarity with organic synthesis made it important for her to first repeat known 
chemistry before transitioning to her own independent project.  This involved 
synthesizing starting material that would later be used to make more significant 
research advancements in the laboratory, therefore embodying Lave’s principle of 
legitimate peripheral participation.93,94 Furthermore, this exercise also served as a 
scaffold97 to help Stanna learn new techniques and become more comfortable with 
procedures in which she had minimal training. One week after her arrival, she described 
her expectations for the exchange program, which mirrored apprenticeship theories of 
learning: 
I’m just really excited to see and pick up on [group members’] lab technique and 
it’s really fun just to kind of watch you guys… [It’s been nice] picking up on how 
you guys set up reactions and decide when to do things.  I also really enjoy 
hearing you guys talk to each other about different things. 
 
As most commonly examined in the literature,89 undergraduate research 
experiences typically result in significant professional development gains, including 
growth as a researcher and increased preparation for a career in the sciences.  Stanna 
noted similar learning outcomes, such as the development of fundamental research 
skills and laboratory techniques as detailed in the first half of Table 4.3.  For example, 
Stanna frequently commented on feeling more comfortable with purification methods 
such as column chromatography and learning to use thin layer chromatography (TLC) 
as a means to track the progress of a chemical reaction.  Many of these new research 
procedures were documented in a “daily diary” which Stanna reported helped to support 
her learning by allowing her to better remember information. In other words, by writing 
notes and drawing figures of new laboratory techniques Stanna was able to make her 
learning experiences more permanent and useful to herself in the future.  She also 
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mentioned that participating in group-based problem solving sessions and focusing on 
more exploratory research aims helped her to acquire new critical thinking strategies, 
which was one of her primary learning goals throughout this process. 
 
Table 4.3 – Learning Outcomes Perceived by Stanna from 10-Week Visit to the 
Montgomery Lab 
 
According to the NRC’s How People Learn,114 the transfer of knowledge to new 
settings and situations is an active learning strategy which is commonly used by experts 
who have a deep understanding of a particular subject matter and how it is applied in 
different contexts.  When I interviewed Stanna two months after the program, she told 
me she had already started employing a few of these strategies to help advance her 
research in the Johnson lab.  For example, Stanna mentioned she was now frequently 
utilizing the literature as a resource to troubleshoot problems and continuing to use TLC 
as a tool to monitor reaction conversion, both approaches she had not made use of 
before coming to the University of Michigan.  Furthermore, Stanna’s visitation 
experience also gave her a much better understanding about graduate school and 
affirmed it was the right career path for her.  She later recalled this being one of her 
primary motivations for wanting to conduct research at an external R1 institution: 
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“[G]oing into the summer I think the only expectation I had was that it would be a taste 
of grad school.”  In addition, after working in the Montgomery lab Stanna began to 
consider issues related to graduate programs that she had not previously thought about 
such as graduation requirements, mentorship style of the professors, access to 
equipment, and location of the university. 
Stanna also commented on the added benefits of being directly mentored by 
students who were significantly more experienced than most of her co-workers in the 
Johnson lab.  While she recognized significant parallels between both laboratories’ 
mentorship practices, she acknowledged that the resources available to her in the 
Montgomery lab helped her to move beyond her unassisted capabilities in a way that 
was not possible in the Johnson lab.  In this sense, Stanna was able to expand her 
zone of proximal development96 beyond what was previously conceivable, highlighting a 
benefit of the exchange program.  The experience also challenged her to move outside 
of her comfort zone by confronting difficult tasks that she often purposefully avoided in 
the Johnson lab.  This allowed her to become more confident and independent in her 
research skills, which Stanna described as one of her primary goals for the summer: 
And so to be forced to learn how to do those things it’s really good for me and so 
while I feel like I definitely could have gotten better…at Hope, I definitely wouldn’t 
have gotten as comfortable as I am now [doing research] had I not come here. 
 
 As described earlier, Lave defined advancement in a community of practice as 
being not only correlated to an increase in knowledge and skills, but a change in social 
identity.93,94 By the end of her research experience, Stanna not only felt that she had 
made a lot of professional connections, but sensed she had been fully apprenticed into 
the lab family: “But what I love about the lab is you guys are all so welcoming and you 
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all felt like my older siblings – like I’m the baby of the family and I just ask anybody 
questions.  That was cool.”  In addition to identifying as a member of the Montgomery 
lab community, Stanna also discussed how she became more self-aware of her identity 
as a learner.  As she mentioned in her second interview with me: “And I think…the more 
different personalities I see, the better I find out how I work.”  By becoming closely 
connected with Montgomery lab members, Stanna was able to relate to others and 
realize her own work-style preferences, consequently learning more about herself in the 
process. 
 
4.5 Conclusions and Future Directions 
 Ultimately, we found our R1/PUI exchange program to be a worthwhile 
professional development experience which is well explained using situated theories of 
learning.  By exchanging places in each other’s communities of practice, Stanna and I 
experienced significant cognitive and personal gains that could not be duplicated if we 
had stayed place in our respective laboratories.  While I learned important lessons on 
the importance of independence and enjoyment in students’ laboratory learning, I also 
left the experience much happier than when I had started, having regained confidence 
and rediscovered my love for chemistry and teaching.  Similarly, Stanna obtained a 
range of new skills and insights that are transferable to the next phase of her education.  
These lessons will not only help her to achieve success in her future research, but 
provide her with the confidence and determination to keep going on the days when this 
success may feel out of reach.  In the end we feel these results support our claim that 
graduate/undergraduate exchange programs are relatively underexplored career 
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development opportunities that should be utilized more often to better prepare students 
for the next stages of their professional lives. 
 While I could not have acquired such detailed insight from simply visiting the 
Johnson laboratory, it is unclear how significantly these outcomes would be affected if a 
similar scenario were repeated in the absence of data collection and analysis.  It would 
be unreasonable for us to suggest that future exchange program participants replicate 
these practices; however, at a very minimum we advise that students take full 
advantage of such opportunities by fully engaging with others and taking time for 
personal reflection.  We also recommend that future research efforts examine students’ 
outcomes from a fully external perspective (i.e. the researcher is not also a participant in 
the exchange program) and that studies focus on exchange programs in different 
settings and research areas to support more widespread understanding of and 
implementation of these experiences. 
 Logistical details and descriptions of learning gains from this study will be 
published in the near future, likely in a format which is easily accessible to the broader 
scientific community.  In doing so, we hope that our work will not only inspire further 
research efforts but will promote the design of similar exchange program opportunities 
to better prepare students for careers in the sciences. 
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CHAPTER V 
Supporting Information 
 
5.1 General Experimental Details 
Unless otherwise noted, all reactions were conducted in flame‐ dried or oven-
dried glassware with magnetic stirring under an atmosphere of dry nitrogen.  Reaction 
temperatures were controlled using an IKA RCT basic stir plate with ETS-D5 electronic 
contact thermometer.  Solvents were purified under nitrogen using a solvent purification 
system (Innovative Technology, Inc., Model #SPS‐ 400‐ 3 and PS‐ 400‐ 3).  (+)-B-
allyldiisopinocampheylborane,117 and 2-((dimethylamino)methyl)benzoic acid,62 and 
azidobenzoic acids77 were synthesized according to previously reported procedures.  
Methacryloyl chloride (Sigma-Aldrich), Et3N, and oxalyl chloride were distilled prior to 
use.  (+)-B-Methoxydiisopinocampheylborane (Sigma-Aldrich), and Grubbs catalyst (2nd 
generation, Sigma-Aldrich) were stored and weighed in an inert atmosphere glovebox.  
Unless stated otherwise, all other chemical reagents were obtained from commercial 
sources and used as received.   
Analytical thin layer chromatography (TLC) was performed on SiliaPlate TLC 60Å 
F-254 (250 μm silica gel) and compounds were visualized with ceric ammonium 
molybdate or aqueous KMnO4 stain.  Flash column chromatography was performed 
using SiliaFlash® P60 (230‐ 400 mesh) silica gel.  
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1 H-Nuclear Magnetic Resonance (1 H-NMR) and 13 C-Nuclear Magnetic 
Resonance (13 C-NMR) spectra were recorded on Varian MR 400, Vnmrs 500, INOVA 
500 and Vnmrs 700 MHz.  NMR spectra were recorded in deuterated chloroform 
(CDCl3) at room temperature.  High-resolution mass spectra were recorded on a VG 70-
250-s spectrometer manufactured by Micromass Corp. (Manchester UK) at the 
University of Michigan Mass Spectrometry Laboratory. 
 
5.2 Synthesis of Tirandamycin Analogs 
5.2.1 Bicycle Synthesis 
 
 
 
 
Scheme 2.9, Compound 53 ((S)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)acetaldehyde): 
 
(4S)-(+)-4-(2-Hydroxyethyl)-2,2-dimethyl-1,3-dioxolane (52, 6.54 mL, 46.0 mmol, 1.0 
equiv) was added to a flame-dried round bottom flask containing pyridinium 
chlorochromate (19.8 g, 92.0 mmol, 2.0 equiv), DCM (250 mL) and celite (20 g).  The 
reaction was allowed to stir for approximately 2 hours and the resulting slurry filtered 
through a layered plug of celite and silica with ether.  The filtrate was then slowly 
concentrated by rotary evaporation using an iced water bath to avoid loss of the volatile 
product.  Residual chromium was removed via column chromatography (30 - 50% 
Et2O/pentane) to give 53 (3.91 g, 27.1 mmol, 59%).  The spectra matched that of 
previous reports.118 
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Scheme 2.9, Compound 54 ((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)pent-4-en-2-
ol): 
 
A solution of aldehyde 53 (2.72 g, 18.9 mmol, 1.0 equiv) in toluene (13 mL) was added 
dropwise to a cooled slurry of (+)-B-allyldiisopinocampheylborane117 (7.39 g, 22.7 
mmol,1.2 equiv) in toluene (20 mL) at  -78 oC.  The resulting mixture was stirred at -78 
oC for 1.5 hours and then warmed to room temperature while stirring for an additional 
hour.  The mixture was cooled to 0 oC and a premixed solution of 3M NaOH (36 mL), 
and 30% H2O2 (15 mL) was slowly added over 10 minutes using an addition funnel, 
followed by addition of saturated aq. NaHCO3 (45 mL) over 3 minutes.  The biphasic 
mixture was then allowed to stir for ~12 hours to hydrolyze borinate ester products.  The 
organic and aqueous layers were separated and the aqueous layer was extracted twice 
with ether.  The combined organic layers were then washed twice with brine and 
transferred to a round bottom flask.  THF (85 mL), H2O (45 mL), and iron (II) sulfate 
heptahydrate salt (8.5 g) were added and the biphasic mixture was stirred for another 
~12 hours.  The two layers were separated and the aqueous layer was extracted two 
times with ether.  The combined organic layers were washed with brine, dried over 
Na2SO4, filtered, and concentrated.  Purification by column chromatography (10-30% 
EtOAc/Hexanes) afforded 54 (1.82 g, 9.76 mmol, 52%), which matched that of previous 
reports.119 
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Scheme 2.9, Compound 55 ((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)pent-4-en-2-yl 
methacrylate): 
 
To a flame-dried round bottom flask equipped with a stir bar was added 54 (1.87 g, 10.0 
mmol, 1.0 equiv), DMAP (612 mg, 5.01 mmol, 0.5 equiv), Et3N (7.00 mL, 50.1 mmol, 5.0 
equiv) and DCM (10 mL). The solution was cooled to 0 oC and methacryloyl chloride 
(1.96 mL, 20.0 mmol, 2.0 equiv) was slowly added.  The resulting reaction mixture was 
allowed to warm to room temperature and stirred until completion, as judged by TLC.  
The mixture was then diluted with saturated aq. NaHCO3 and brine, the organic layer 
separated, and the aqueous layer extracted three times with ether.  The combined 
organic layers were dried over MgSO4, filtered, concentrated, and purified by column 
chromatography (10% EtOAc/Hexanes) to give the title compound (1.87 g, 7.35 mmol, 
73%). 
1H NMR (500 MHz, CDCl3): δ 6.21 – 5.93 (m, 1H), 5.82 – 5.69 (m, 1H), 5.60 – 5.50 (m, 
1H), 5.18 – 5.00 (m, 3H), 4.17 – 4.06 (m, 1H), 4.00 (dd, J = 8.0, 5.9 Hz, 1H), 3.52 (t, J = 
7.6 Hz, 1H), 2.49 – 2.31 (m, 2H), 2.01 – 1.88 (m, 4H), 1.87 – 1.76 (m, 1H), 1.39 (s, 3H), 
1.32 (s, 3H). 
 
13C NMR (176 MHz, CDCl3): δ 166.74, 136.41, 133.07, 125.44, 118.24, 108.60, 73.34, 
71.25, 69.76, 39.11, 37.85, 26.94, 25.70, 18.30. 
 
HRMS (ESI+) m/z: [M+Na]+ predicted for C14H22O4Na, 277.1410; found 277.1410. 
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Scheme 2.9, Compound 56 ((R)-6-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-3-
methyl-5,6-dihydro-2H-pyran-2-one): 
 
To a flame-dried three-necked flask equipped with a reflux condenser was added 55 
(866 mg, 3.41 mmol, 1.0 equiv), tetrafluoro-1,4-benzoquinone (61.3 mg, 0.34 mmol, 0.1 
equiv), and toluene (680 mL), followed by Grubbs’ catalyst (145 mg, 0.17 mmol, 0.05 
equiv).  The reaction was heated for ~12 hours at 60 oC while sparging with N2.  A 
solution of Grubbs’ catalyst (145 mg, 0.17 mmol, 0.05 equiv) was then added in 1 mL 
toluene and the reaction was allowed to stir for another ~2 hours or until complete 
conversion was observed by TLC.  The resulting solution was cooled to room 
temperature, concentrated in vacuo and purified by column chromatography (7-30% 
EtOAc/Hexanes) to afford the final product (757 mg, 3.35 mmol, 98%). 
1H NMR (700 MHz, CDCl3): δ 6.59 – 6.55 (m, 1H), 4.65 – 4.55 (m, 1H), 4.42 – 4.33 (m, 
1H), 4.12 (dd, J = 8.1, 6.0 Hz, 1H), 3.55 (dd, J = 8.1, 7.1 Hz, 1H), 2.43 – 2.25 (m, 2H), 
1.97 (ddd, J = 14.3, 9.4, 3.6 Hz, 1H), 1.93 – 1.89 (m, 3H), 1.81 (ddd, J = 14.2, 9.0, 3.3 
Hz, 1H), 1.40 (s, 3H), 1.35 (s, 3H). 
 
13C NMR (176 MHz, CDCl3): δ 165.66, 138.73, 128.53, 109.00, 75.38, 72.10, 69.55, 
39.46, 30.37, 26.99, 25.61, 17.03. 
 
HRMS (ESI+) m/z: [M+H]+ predicted for C12H19O4, 227.1278; found 277.1276. 
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Scheme 2.9, Compound 57 (((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-7-
en-3-yl)methanol): 
 
To a flame-dried round bottom flask was added a solution of 56 (206 mg, 0.91 mmol, 
1.0 equiv) in THF (18 mL).  The solution was cooled to -78 oC and then MeLi (626 L, 
1.6 M solution in Et2O, 1.00 mmol) was slowly added.  The resulting mixture was 
allowed to stir for 4 hours and then quenched by addition of saturated aq. NH4Cl.  The 
organic layer was then separated and the aqueous layer extracted three times with 
EtOAc.  The combined organic extracts were dried with MgSO4, filtered, concentrated, 
and used immediately in the next step without further purification. 
The crude hemiketal and p-PTS (22.9 mg, 0.09 mmol, 0.1 equiv) were dissolved in 
EtOH (15 mL) and stirred for ~12 hours at 50 oC.  The reaction was then quenched by 
addition of saturated aq. NaHCO3.  The organic layer was then separated and the 
aqueous layer extracted three times with Et2O.  The combined organic layers were then 
dried over MgSO4, filtered, and concentrated in vacuo.  The resulting crude product was 
purified by column chromatography (7-30% EtOAc/Hexanes) to give the title bicyclic 
ketal (118 mg, 0.64 mmol, 71% over two steps). 
1H NMR (500 MHz, CDCl3): δ 5.84 – 5.67 (m, 1H), 4.34 (t, J = 6.6 Hz, 1H), 4.03 (ddt, J 
= 12.6, 6.3, 3.3 Hz, 1H), 3.64 – 3.55 (m, 1H), 3.54 – 3.45 (m, 1H), 2.73 – 2.58 (m, 1H), 
2.10 – 2.03 (m, 1H), 2.03 – 1.95 (m, 1H), 1.93 – 1.85 (m, 1H), 1.67 – 1.61 (m, 3H), 1.42 
(s, 3H), 1.24 (ddd, J = 13.3, 3.2, 1.2 Hz, 1H). 
 
13C NMR (176 MHz, CDCl3): δ 132.69, 123.76, 95.59, 68.31, 66.28, 66.16, 31.55, 
30.39, 24.66, 18.74. 
 
HRMS (ESI+) m/z: [M+H]+ predicted for C10H16O3, 185.1172; found 185.1170. 
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Scheme 2.10, Compound 58 ((1S,3S,5S)-3-(hydroxymethyl)-1,8-dimethyl-2,9-
dioxabicyclo[3.3.1]non-7-en-6-one): 
 
To a flame-dried round bottom flask under a nitrogen atmosphere was added 57 (102 
mg, 0.56 mmol, 1.0 equiv), 3 Å molecular sieves (530 mg), and anhydrous EtOAc (6 
mL).  tert-Butyl hydroperoxide (1.04 mL, 5-6 M solution in decane, 5.71 mmol) was then 
slowly added and the resulting mixture was allowed to stir for 30 minutes at room 
temperature.  Manganese (III) acetate dihydrate (29.7 mg, 0.11 mmol, 0.2 equiv) was 
added as a solution in EtOAc (~1 mL) and the reaction was stirred for 48 hours, or until 
complete, as judged by TLC.  The mixture was then filtered through celite, 
concentrated, and purified by column chromatography (17-70% EtOAc/Hexanes) to 
afford the allylic ketone (49.2 mg, 0.25 mmol, 45%). 
1H NMR (500 MHz, CDCl3): δ 6.17 (s, 1H), 4.35 (d, J = 6.0 Hz, 1H), 3.90 (ddt, J = 12.3, 
6.0, 3.1 Hz, 1H), 3.63 (dd, J = 11.9, 3.1 Hz, 1H), 3.54 (dd, J = 11.8, 5.6 Hz, 1H), 2.09 
(m, 1H), 1.97 (d, J = 1.6 Hz, 3H), 1.91 (s, 1H), 1.55 (s, 3H), 1.50 (ddd, J = 13.7, 3.1, 1.5 
Hz, 1H). 
 
13C NMR (126 MHz, CDCl3): δ 196.91, 156.59, 127.09, 96.21, 74.49, 68.77, 65.61, 
27.92, 24.77, 19.59. 
 
HRMS (ESI+) m/z: [M+NH4]+ predicted for C10H18O4N, 216.1230; found 216.1231. 
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Scheme 2.10, Compound 59 (1S,3S,5S,6S)-3-(hydroxymethyl)-1,8-dimethyl-2,9-
dioxabicyclo[3.3.1]non-7-en-6-ol: 
 
A solution of 58 (14.8 mg, 0.08 mmol, 1.0 equiv) in MeOH (1 mL) and cooled to 0 oC.  
NaBH4 (8.50 mg, 0.22 mmol, 3.0 equiv) was added and the reaction was allowed to stir 
until completion, as judged by TLC.  Amberlite 120 ion exchange resin was then added 
and allowed to stir for ~10 minutes.  The mixture was filtered with MeOH over celite and 
concentrated in vacuo.  The residue was then co-evaporated 3 times with MeOH and 
purified by column chromatography to give a single diastereomer (9.40 mg, 0.05 mmol, 
63%). 
1H NMR (700 MHz, CDCl3): δ 5.71 (s, 1H), 4.67 – 4.58 (m, 1H), 4.20 (t, J = 6.4 Hz, 1H), 
3.97 (ddt, J = 9.5, 6.4, 3.7 Hz, 1H), 3.62 (dd, J = 11.6, 3.2 Hz, 1H), 3.52 (dd, J = 11.6, 
6.1 Hz, 1H), 2.01 (s, 1H), 1.87 – 1.74 (m, 3H), 1.69 – 1.61 (m, 3H), 1.41 (s, 3H). 
 
13C NMR (176 MHz, CDCl3): δ 134.52, 128.12, 95.59, 69.72, 68.49, 66.13, 65.60, 
24.50, 23.30, 18.16. 
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Scheme 2.10, Compound 60 (1S,2S,4R,6S,8S)-8-(hydroxymethyl)-1,2-dimethyl-
3,9,10-trioxatricyclo[4.3.1.02,4]decan-5-one: 
 
To a flame-dried reaction tube equipped with a stir bar was added a solution of 58 (7.7 
mg, 0.04 mmol, 1.0 equiv) in THF (0.5 mL) under nitrogen.  DBU (31.0 L, 0.21 mmol, 
5.3 equiv) was then added, followed by tert-Butyl hydroperoxide (37.8 L, 5.5 M solution 
in decane, 0.21 mmol), and the resulting reaction mixture was heated to 60 oC for ~12 
hours.  The reaction vessel was cooled to room temperature and the mixture diluted 
with DCM and washed with 1M HCl.  The aqueous layer was extracted with DCM and 
the combined organic layers washed with H2O.  The aqueous layer was extracted again 
with DCM and the combined organic layers dried over MgSO4, filtered, and 
concentrated in vacuo.  Purification by column chromatography (50-70% 
EtOAc/Hexanes) afforded the final product (1.90 mg, 0.01 mmol, 23%). 
1H NMR (700 MHz, CDCl3): δ 4.38 – 4.33 (m, 1H), 4.04 – 3.97 (m, 1H), 3.62 (dd, J = 
11.8, 3.1 Hz, 1H), 3.52 (dd, J = 11.8, 5.9 Hz, 1H), 3.38 (s, 1H), 2.08 – 1.99 (m, 1H), 1.58 
– 1.54 (m, 4H), 1.50 (s, 3H). 
 
13C NMR (176 MHz, CDCl3): δ 205.31, 97.27, 74.48, 68.74, 65.69, 62.11, 58.42, 29.56, 
23.09, 15.89. 
 
HRMS (ESI+) m/z: [M+H]+ predicted for C10H15O5, 215.0914; found 215.0918. 
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5.2.2 Anchor Attachment 
 
General DCC Coupling Procedure: 
To a flame-dried reaction vessel was added tirandamycin bicycle (1.0 equiv), benzoic 
acid (1.5 equiv), DCC (1.5 equiv), DMAP (0.15 equiv) and DCM (0.1M).  The resulting 
mixture was allowed to stir for ~30 minutes, or until complete as judged by TLC.  The 
crude mixture was then filtered twice through cotton and purified by column 
chromatography. 
 
General EDC Coupling Procedure: 
To a flame-dried reaction vessel was added tirandamycin bicycle (1.0 equiv), 
azidobenzoic acid77 (5.0 equiv), EDC•HCl (5.0 equiv), DMAP (1.0 equiv) and DCM 
(0.05M).  The resulting mixture was allowed to stir until complete as judged by TLC.  
The crude mixture was then concentrated and purified by column chromatography. 
 
General Reductive Amination Procedure: 
To a mixture of aldehyde (1.0 equiv) in DCM (0.15M) was added dimethyl amine 
hydrochloride (1.3 equiv) and the resulting reaction mixture was allowed to stir for ~30 
minutes.  The solution was then cooled to 0 oC and NaBH(OAc)3 (1.5 equiv) was slowly 
added and stirred for ~12 hours.  The reaction mixture was diluted with EtOAc and 
washed twice with saturated aq. NaHCO3 and then once with 3:1 NaCl:NaHCO3 
solution.  The organic phase was then dried over MgSO4, filtered, and concentrated to 
yield a mixture of amine and alcohol.  The resulting residue was then dissolved in 0.1M 
HCl and washed three times with 30% EtOAc/Hexanes.  The aqueous layer was 
basified with saturated aq. NaHCO3 until the pH increased to 8-9 and then extracted 
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three times with DCM.  The combined organic layers were dried with Na2SO4, filtered 
and concentrated in vacuo. 
 
General Click Cyclization Procedure: 
Azido ester (1.0 equiv) and alkyne (1.0 equiv) were dissolved a 1:1 solution of H2O/t-
BuOH.  Sodium ascorbate (10 mol%) and CuSO4•5H2O (1 mol%) were then added 
sequentially and the reaction was allowed to stir until the starting material was 
consumed as judged by TLC. Upon completion, the reaction was quenched with 
saturated aq. NaHCO3 and the aqueous layer extracted five times with DCM.  The 
organic layers were then combined, dried over NaSO4, filtered, and concentrated. The 
crude residue was purified by column chromatography to yield the desired substrate. 
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Figure 3.3/3.6, Compound 81 ((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-
7-en-3-yl)methyl 4-((dimethylamino)methyl)benzoate: 
 
Following the general DCC coupling procedure, the reaction of 23.0 mg (0.13 mmol) of 
57, 28.1 mg (0.19 mmol) of 4-formyl benzoic acid, 38.6 mg (0.19 mmol) of DCC, 2.30 
mg (0.02 mmol) of DMAP, and 1.3 mL of DCM afforded 33.2 mg (0.10 mmol, 84%) of 
the desired aryl ester, which was purified by column chromatography (15% 
EtOAc/Hexanes) and carried on directly to the next step. 
 
Following the general reductive amination procedure, the reaction of 33.2 mg (0.11 
mmol) of ((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-7-en-3-yl)methyl 4-
formylbenzoate, 11.1 mg (0.14 mmol) of dimethyl amine hydrochloride, 33.4 mg (0.16 
mmol) NaBH(OAc)3, and 1 mL of DCM afforded 10.9 mg (0.03 mmol, 30%) of the title 
compound. 
1H NMR (500 MHz, CDCl3): δ 8.05 – 7.94 (m, 2H), 7.43 – 7.34 (m, 2H), 5.83 – 5.76 (m, 
1H), 4.37 (t, J = 6.7 Hz, 1H), 4.33 – 4.24 (m, 3H), 3.47 (s, 2H), 2.76 – 2.62 (m, 1H), 2.24 
(s, 6H), 2.09 – 1.97 (m, 1H), 1.97 – 1.87 (m, 1H), 1.70 – 1.62 (m, 3H), 1.45 (s, 3H), 1.44 
– 1.39 (m, 1H). 
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Figure 3.3/3.6, Compound 82 ((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-
7-en-3-yl)methyl 3-((dimethylamino)methyl)benzoate: 
 
Following the general DCC coupling procedure, the reaction of 31.3 mg (0.17 mmol) of 
57, 38.2 mg (0.25 mmol) of 3-formyl benzoic acid, 52.5 mg (0.25 mmol) of DCC, 3.10 
mg (0.03 mmol) of DMAP, and 1.8 mL of DCM afforded 29.1 mg (0.09 mmol, 54%) of 
the desired aryl ester, which was purified by column chromatography (15% 
EtOAc/Hexanes) and carried on directly to the next step. 
 
Following the general reductive amination procedure, the reaction of 29.1 mg (0.09 
mmol) of ((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-7-en-3-yl)methyl 3-
formylbenzoate, 9.75 mg (0.12 mmol) of dimethyl amine hydrochloride, 29.2 mg (0.14 
mmol) NaBH(OAc)3, and 1 mL of DCM afforded 14.7 mg (0.04 mmol, 46%) of the title 
compound. 
1H NMR (500 MHz, CDCl3): δ 7.98 – 7.89 (m, 2H), 7.58 – 7.48 (m, 1H), 7.40 (t, J = 7.6 
Hz, 1H), 5.84 – 5.75 (m, 1H), 4.37 (t, J = 6.6 Hz, 1H), 4.33 – 4.25 (m, 3H), 3.47 (s, 2H), 
2.75 – 2.62 (m, 1H), 2.25 (s, 6H), 2.11 – 1.98 (m, 1H), 1.95 – 1.87 (m, 1H), 1.71 – 1.63 
(m, 3H), 1.45 (s, 3H), 1.44 – 1.39 (m, 1H). 
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Figure 3.3/3.6, Compound 83 ((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-
7-en-3-yl)methyl 2-((dimethylamino)methyl)benzoate: 
 
To a flame-dried 1-dram vial was added 2-((dimethylamino)methyl)benzoic acid62 (43.0 
mg, 0.24 mmol, 1.0 equiv), followed by 3 drops of DMF and oxalyl chloride (23.0 L, 
0.27 mmol, 1.1 equiv).  The reaction mixture was allowed to stir at room temperature for 
1.5 hours and then concentrated in vacuo and resuspended in DCM (1.5 mL).  The acyl 
chloride suspension was then added dropwise to an iced solution of 57 (50.0 mg, 0.27 
mmol, 1.1 equiv), DMAP (14.7 mg, 0.12 mmol, 0.5 equiv), and Et3N (168 L, 1.20 mmol, 
5.0 equiv) in DCM (1.8 mL).  The mixture was allowed to stir until completion, with 
addition of more acyl chloride if necessary.  The reaction was quenched with saturated 
aq. NaHCO3 and washed three times with EtOAc.  The combined organic layers were 
then dried with sodium sulfate, filtered, and concentrated to give the title compound 
(26.4 mg, 0.078 mmol, 32%) following purification by column chromatography. 
1H NMR (500 MHz, CDCl3): δ 7.80 (d, J = 7.7 Hz, 1H), 7.54 – 7.39 (m, 2H), 7.31 (t, J = 
7.5 Hz, 1H), 5.83 – 5.74 (m, 1H), 4.37 (t, J = 6.6 Hz, 1H), 4.33 – 4.19 (m, 3H), 3.79 (q, J 
= 13.6 Hz, 2H), 2.76 – 2.59 (m, 1H), 2.26 (s, 6H), 2.02 (td, J = 12.4, 6.2 Hz, 1H), 1.96 – 
1.86 (m, 1H), 1.66 (s, 3H), 1.44 (s, 3H), 1.42 – 1.37 (m, 1H). 
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Figure 3.3/3.6, Compound 84 ((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-
7-en-3-yl)methyl 6-(dimethylamino)hexanoate: 
 
Following the general DCC coupling procedure, the reaction of 31.3 mg (0.17 mmol) of 
57, 49.6 mg (0.25 mmol) of 6-bromohexanoic acid, 52.5 mg (0.25 mmol) of DCC, 3.10 
mg (0.03 mmol) of DMAP, and 1.8 mL of DCM afforded 26.4 mg (0.07 mmol, 43%) of 
the desired bromo ester, which was purified by column chromatography and carried on 
directly to the next step.  
 
To a solution of ((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-7-en-3-yl)methyl 6-
bromohexanoate (26.4 mg, 0.07 mmol, 1.0 equiv) in DMF (1 mL) was added 
dimethylamine (48 L, 40 % w/w in H2O, 0.38 mmol) and the resulting mixture was 
allowed to stir for ~2 hours.  The reaction was then quenched with saturated aq. 
NaHCO3 solution and extracted three times with EtOAc.  The organic layers were 
combined, dried over Na2SO4, and concentrated in vacuo.  Purification by column 
chromatography afforded the final product (14.9 mg, 0.05 mmol, 63%). 
1H NMR (400 MHz, CDCl3): δ 5.86 – 5.67 (m, 1H), 4.34 (t, J = 6.6 Hz, 1H), 4.21 – 3.96 
(m, 3H), 2.75 – 2.56 (m, 1H), 2.39 – 2.28 (m, 2H), 2.27 – 2.14 (m, 8H), 1.98 – 1.82 (m, 
2H), 1.71 – 1.57 (m, 5H), 1.53 – 1.44 (m, 2H), 1.42 (s, 3H), 1.39 – 1.27 (m, 3H). 
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Figure 3.3/3.6, Compound 87 ((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-
7-en-3-yl)methyl 4-(4-((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate: 
 
Following the general EDC coupling procedure, the reaction of 30.0 mg (0.16 mmol) of 
57, 133 mg (0.81 mmol) of 4-azidobenzoic acid, 156 mg (0.81 mmol) of EDC•HCl, 19.9 
mg (0.16 mmol) of DMAP, and 3.3 mL of DCM afforded 44.4 mg (0.13 mmol, 83%) of 
the desired azido ester, which was purified by column chromatography (0 to 10% 
EtOAc/Hexanes) and carried on directly to the next step.  
 
Following the general click cyclization procedure, the reaction of 44.4 mg (0.13 mmol) of 
((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-7-en-3-yl)methyl 4-azidobenzoate, 
15 L (0.14 mmol) N,N-dimethylprop-2-yn-1- amine, 10.0 x 10-3 mmol sodium 
ascorbate, 1.00 x 10-3 mmol CuSO4•5H2O, and 1 mL H2O/t-BuOH (1:1) afforded 38.7 
mg (0.09 mmol, 69%) of the title compound after purification by column 
chromatography. 
1H NMR (500 MHz, CDCl3): δ 8.25 – 8.14 (m, 2H), 8.01 (s, 1H), 7.89 – 7.78 (m, 2H), 
5.83 – 5.77 (m, 1H), 4.38 (t, J = 6.6 Hz, 1H), 4.35 – 4.27 (m, 3H), 3.69 (s, 2H), 2.75 – 
2.62 (m, 1H), 2.32 (s, 6H), 2.11 – 1.98 (m, 1H), 1.98 – 1.88 (m, 1H), 1.70 – 1.62 (m, 
3H), 1.45 (s, 3H), 1.43 – 1.38 (m, 1H). 
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Figure 3.3/3.6, Compound 88 ((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-
7-en-3-yl)methyl 3-(4-((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate: 
 
Following the general EDC coupling procedure, the reaction of 30.0 mg (0.16 mmol) of 
57, 133 mg (0.81 mmol) of 3-azidobenzoic acid, 156 mg (0.81 mmol) of EDC•HCl, 19.9 
mg (0.16 mmol) of DMAP, and 3.3 mL of DCM afforded 48.5 mg (0.15 mmol, 90%) of 
the desired azido ester, which was purified by column chromatography and carried on 
directly to the next step.  
 
Following the general click cyclization procedure, the reaction of 48.5 mg (0.15 mmol) of 
((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-7-en-3-yl)methyl 3-azidobenzoate, 
16 L (0.15 mmol) N,N-dimethylprop-2-yn-1- amine, 10.0 x 10-3 mmol sodium 
ascorbate, 1.00 x 10-3 mmol CuSO4•5H2O, and 1 mL H2O/t-BuOH (1:1) afforded 39.2 
mg (0.09 mmol, 65%) of the title compound after purification by column 
chromatography. 
1H NMR (500 MHz, CDCl3): δ 8.38 – 8.29 (m, 1H), 8.13 – 8.06 (m, 1H), 8.05 – 7.96 (m, 
2H), 7.61 (t, J = 7.9 Hz, 1H), 5.83 – 5.76 (m, 1H), 4.37 (t, J = 6.6 Hz, 1H), 4.35 – 4.28 
(m, 3H), 3.70 (s, 2H), 2.75 – 2.60 (m, 1H), 2.33 (s, 6H), 2.09 – 1.96 (m, 1H), 1.96 – 1.87 
(m, 1H), 1.70 – 1.60 (m, 3H), 1.47 – 1.38 (m, 4H). 
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Figure 3.3/3.6, Compound 89 ((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-
7-en-3-yl)methyl 2-(4-((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate: 
 
Following the general EDC coupling procedure, the reaction of 30.0 mg (0.16 mmol) of 
57, 133 mg (0.81 mmol) of 2-azidobenzoic acid, 156 mg (0.81 mmol) of EDC•HCl, 19.9 
mg (0.16 mmol) of DMAP, and 3.3 mL of DCM afforded 43.9 mg (0.13 mmol, 82%) of 
the desired azido ester, which was purified by column chromatography and carried on 
directly to the next step.  
 
Following the general click cyclization procedure, the reaction of 43.9 mg (0.13 mmol) of 
((1R,3S,5R)-1,8-dimethyl-2,9-dioxabicyclo[3.3.1]non-7-en-3-yl)methyl 2-azidobenzoate, 
14 L (0.13 mmol) N,N-dimethylprop-2-yn-1- amine, 10.0 x 10-3 mmol sodium 
ascorbate, 1.00 x 10-3 mmol CuSO4•5H2O, and 1 mL H2O/t-BuOH (1:1) afforded 41.2 
mg (0.10 mmol, 75%) of the title compound after purification by column 
chromatography. 
1H NMR (500 MHz, CDCl3): δ 8.03 – 7.94 (m, 1H), 7.76 (s, 1H), 7.69 – 7.62 (m, 1H), 
7.62 – 7.55 (m, 1H), 7.51 – 7.43 (m, 1H), 5.79 – 5.73 (m, 1H), 4.30 (t, J = 6.6 Hz, 1H), 
4.15 – 4.08 (m, 2H), 4.08 – 4.00 (m, 1H), 3.70 (s, 2H), 2.70 – 2.56 (m, 1H), 2.33 (s, 6H), 
1.94 – 1.77 (m, 2H), 1.66 – 1.57 (m, 3H), 1.39 (s, 3H), 1.31 – 1.20 (m, 1H). 
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Figure 3.5/3.6, Compound 92 ((1S,3S,5S)-1,8-dimethyl-6-oxo-2,9-
dioxabicyclo[3.3.1]non-7-en-3-yl)methyl 3-((dimethylamino)methyl)benzoate: 
 
Following the general DCC coupling procedure, the reaction of 14.9 mg (0.08 mmol) of 
58, 16.9 mg (0.11 mmol) of 3-formyl benzoic acid, 23.3 mg (0.11 mmol) of DCC, 1.40 
mg (0.01 mmol) of DMAP, and 1.0 mL of DCM afforded 15.7 mg (0.05 mmol, 63%) of 
the desired aryl ester, which was purified by column chromatography and carried on 
directly to the next step. 
 
Following the general reductive amination procedure, the reaction of 15.7 mg (0.05 
mmol) of ((1S,3S,5S)-1,8-dimethyl-6-oxo-2,9-dioxabicyclo[3.3.1]non-7-en-3-yl)methyl 3-
formylbenzoate, 5.00 mg (0.06 mmol) of dimethyl amine hydrochloride, 15.1 mg (0.71 
mmol) NaBH(OAc)3, and 1 mL of DCM afforded 7.30 mg (0.02 mmol, 42%) of the title 
compound. 
1H NMR (700 MHz, CDCl3): δ 7.96 – 7.93 (m, 1H), 7.91 (d, J = 7.8 Hz, 1H), 7.55 (d, J = 
7.6 Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 6.20 (s, 1H), 4.39 (d, J = 6.0 Hz, 1H), 4.34 (dd, J = 
11.5, 5.7 Hz, 1H), 4.29 (dd, J = 11.5, 4.5 Hz, 1H), 4.21 – 4.13 (m, 1H), 3.47 (s, 2H), 2.25 
(s, 6H), 2.11 (td, J = 13.1, 6.3 Hz, 1H), 1.98 (d, J = 1.4 Hz, 3H), 1.69 (ddd, J = 13.6, 3.1, 
1.6 Hz, 1H), 1.57 (s, 3H). 
 
13C NMR (176 MHz, CDCl3): δ 196.58, 166.31, 156.53, 139.46, 134.02, 130.32, 129.83, 
128.56, 128.53, 127.17, 96.25, 74.47, 66.82, 66.39, 63.93, 45.40, 29.04, 24.68, 19.52. 
 
HRMS (ESI+) m/z: [M+H]+ predicted for C20H26NO5, 360.1805; found 360.1805. 
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5.3 Biochemical Oxidations 
 
Preparation of PikC-RhFRED mutants:  
PikC mutants were prepared following previously established protocols.63,75  
 
Expression and purification of PikC-RhFRED and TamI-RhFRED: 
The plasmid encoding the respective fusion protein was transformed into E. coli 
BL21(DE3) cells, and an individual colony was selected for overnight growth (37 °C) in 
250 mL of LB containing kanamycin (50 μg/mL). 12 x 1.5 L of LB (2.8 L baffled 
Fernbach flasks) supplemented with kanamycin (50 μg/mL), thiamine (1 mM), and FeCl3 
(100 μM) were each inoculated with 15 mL of overnight seed culture and incubated at 
37 °C (160 rpm). When the OD600 reached 0.6-1.0, the cultures were cooled in an ice-
water bath (15-20 min) before addition of IPTG (0.1 mM) and δ-aminolevulinic acid (1 
mM). The cultures were grown at 18 °C for 18-20 h before the cells were harvested and 
stored at -80 °C until used for protein purification. All subsequent steps were performed 
at 4 °C. The cells were thawed and resuspended in 180 mL of lysis buffer (50 mM 
NaH2PO4, 300 mM NaCl, 10 mM imidazole, 10% glycerol, 1 mM PMSF, pH 8) prior to 
lysis via sonication. The crude lysate was centrifuged at 50,000 x g for 30 min to 
remove cellular debris, and the clarified lysate was incubated with 20 mL of pre-
equilibrated Ni-NTA resin on a nutating shaker for 1-2 h. The slurry was loaded onto an 
empty column, and the lysate was pushed through with gentle syringe pressure. The 
resin was washed with wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 
10% glycerol, pH 8) to remove bulk protein contaminants prior to elution of PikC-
RhFRED/TamI-RhFRED with elution buffer (50 mM NaH2PO4, 300 mM NaCl, 300 mM 
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imidazole, 10% glycerol, pH 8). The protein was subsequently concentrated using 30-50 
kD MWCO centrifugal filters and desalted by loading onto PD-10 columns and eluting 
with storage buffer (50 mM NaH2PO4, 1 mM EDTA, 0.2 mM DTT, 10% glycerol, pH 7.3). 
The purified enzyme was typically used right away for large-scale reactions; any unused 
enzyme was aliquoted, flash frozen in liquid N2, and stored at -80 °C for subsequent use 
in analytical- and/or additional large-scale reactions. 
 
Analytical-scale enzymatic reactions 
Analytical-scale enzymatic reactions were carried out under the following conditions: 5 
μM PikC-RhFRED/TamI-RhFRED, 1 mM substrate (5% DMSO, final concentration), 1 
mM NADP+, 5 mM glucose-6-phosphate, and 1 U/mL glucose-6-phosphate 
dehydrogenase in storage buffer (50 mM NaH2PO4 (pH = 7.3), 1 mM EDTA, 0.2 mM 
DTT, 10% (v/v) glycerol). The total volume of each reaction was 100 μL (carried out in a 
1.7 mL Eppendorf tube), and reactions were incubated at 30 °C (200 rpm) for 14-18 h 
prior to quenching via extraction with chloroform (2 x 100 μL). The combined organic 
layers were dried under a gentle stream of N2 and resuspended in methanol prior to LC-
MS analysis. The subsequent liquid chromatography mass spectrometry (LC-MS) 
analysis was performed on an Agilent Q-TOF HPLC-MS (Department of Chemistry, 
University of Michigan) equipped with an high resolution electrospray mass 
spectrometry (ESI-MS) source and a Beckmann Coulter reverse-phase HPLC system 
using an Waters XBridge C18 3.5 μm, 2.1x150 mm under the following conditions: 
mobile phase (A = deionized water + 0.1% formic acid, B = acetonitrile + 0.1% formic 
acid), 10% to 100% B over 15 min, 100% B for 4 min; flow rate, 0.2 mL/min. Reactions 
were scanned for [M+H] (starting material), [M+H+16] (monohydoxylation), [M+H+32] 
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(dihydroxylation), [M+H-14] (demethylated starting material), and [M+H+2] 
(demethylated monohydroxylated product).  The percent conversion was determined as 
outlined in Li et al.75 Briefly, the percent conversion was calculated with (AUCtotal 
products/(AUCtotal products + AUCunreacted substrate) by assuming ionization 
efficiency of substrate and hydroxylated products are the same, because the ionization 
site of this series of compounds should be the dimethylamino group.75 
 
Preparative-scale enzymatic reactions  
 
To an Erlenmeyer flask containing reaction buffer (50 mM NaH2PO4, 1 mM EDTA, 0.2 
mM DTT, 10% (v/v) glycerol, pH 7.3) were added the following components 
sequentially: substrate (20 mM stock in DMSO, 1 mM final concentration), glucose-6-
phosphate (100 mM stock in reaction buffer, 5 mM final concentration), glucose-6-
phosphate dehydrogenase (100 U/mL stock in water, 1 U/mL final concentration), PikC-
RhFRED/TamI-RhFRED (varied stock concentrations, 5 μM final concentration), and 
NADP+ (20 mM stock in reaction buffer, 1 mM final concentration). The reaction mixture 
was capped with a milk filter and incubated at 30 °C overnight (14-16 h) with gentle 
shaking (100 rpm). Reactions were typically conducted on ~60 mg of each substrate 
(~130 mL total reaction volume) and performed in 500 mL Erlenmeyer flasks. After 
overnight incubation, the reaction was quenched by addition of acetone (2 x total 
reaction volume) and incubated at 4 °C for 2 h. The mixture was then filtered through 
celite, and the acetone was removed under reduced pressure. The remaining aqueous 
solution was saturated with NaCl, adjusted to pH 11, and extracted with ethyl acetate (3 
x total reaction volume). The combined organic layers were dried over anhydrous 
Na2SO4 and evaporated under reduced pressure to afford a crude mixture of products 
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and remaining starting material, which were purified by flash column chromatography. 
Mixtures that were recalcitrant to separation using standard column chromatographic 
techniques were further purified via semi-preparative HPLC using a Beckman Coulter 
System Gold HPLC equipped with a Waters XBridge BEH C18 column (dimensions, 
250 x 10 mm; particle size, 5 μm; pore size, 130 Å). The flow rate was maintained at 3 
mL/min, and the mobile phase consisted of an acetonitrile/water mixture with formic acid 
(0.1%) included as a modifier. All crude material was dissolved in methanol and filtered 
through 0.20 μm PTFE filters (EMD Millipore) prior to manual HPLC injection. UV 
absorption was monitored at 240 nm and 260 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 105 
5.4 LCMS Traces 
5.4.1 Reaction of Substrates with PikCD50ND176QE246A-RhFRED (Figure 3.3) 
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5.4.2 Reaction of 82 with TamI-RhFRED (Figure 3.6) 
 
 
5.5 Enzymatic Product Characterization 
 
 
 
Figure 3.4, Compound 90 ((1R,3S,5R)-8-(hydroxymethyl)-1-methyl-2,9-
dioxabicyclo[3.3.1]non-7-en-3-yl)methyl 3-((dimethylamino)methyl)benzoate: 
 
1H NMR (700 MHz, CDCl3): δ 8.01 – 7.96 (m, 1H), 7.92 (dt, J = 7.8, 1.5 Hz, 1H), 7.51 
(dt, J = 7.6, 1.4 Hz, 1H), 7.39 (t, J = 7.7 Hz, 1H), 6.20 – 6.16 (m, 1H), 4.49 – 4.44 (m, 
1H), 4.41 (t, J = 6.5 Hz, 1H), 4.30 – 4.27 (m, 2H), 4.25 – 4.21 (m, 1H), 4.07 – 4.03 (m, 
1H), 3.48 (d, J = 2.2 Hz, 2H), 2.79 – 2.71 (m, 1H), 2.25 (s, 6H), 2.07 – 2.00 (m, 2H), 
1.52 (s, 3H), 1.43 (ddd, J = 13.2, 3.1, 1.3 Hz, 1H). 
 
13C NMR (176 MHz, CDCl3): δ 166.58, 139.19, 135.22, 133.98, 130.54, 130.21, 128.65, 
128.57, 125.95, 95.06, 67.59, 66.44, 65.96, 63.99, 63.40, 45.40, 32.25, 29.88, 24.45. 
 
 HRMS (ESI+) m/z: [M+H]+ predicted for C20H28NO5, 362.1962; found 362.1978. 
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Figure 3.4, Compound 91 ((1S,3S,5S,6S)-6-hydroxy-1,8-dimethyl-2,9-
dioxabicyclo[3.3.1]non-7-en-3-yl)methyl 3-((dimethylamino)methyl)benzoate: 
 
1H NMR (700 MHz, CDCl3): δ 7.96 – 7.94 (m, 1H), 7.94 – 7.92 (m, 1H), 7.55 (d, J = 7.6 
Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 6.00 – 5.97 (m, 1H), 4.31 (d, J = 7.0 Hz, 1H), 4.29 – 
4.27 (m, 2H), 4.16 – 4.09 (m, 1H), 3.76 (d, J = 4.9 Hz, 1H), 3.48 (s, 2H), 2.25 (s, 6H), 
2.06 – 1.97 (m, 1H), 1.75 – 1.68 (m, 3H), 1.50 (dd, J = 13.6, 3.3 Hz, 1H), 1.47 (d, J = 
1.0 Hz, 3H). 
 
13C NMR (176 MHz, CDCl3): δ 166.58, 139.47, 136.83, 134.00, 130.42, 130.08, 128.63, 
128.56, 125.56, 95.59, 73.90, 67.49, 66.35, 65.93, 64.01, 45.46, 28.67, 24.42, 18.62. 
 
HRMS (ESI+) m/z: [M+H]+ predicted for C20H28NO5, 362.1962; found 362.1988. 
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5.6 NMR Spectra 
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5.7 Interview Questions 
5.7.1 Hope College Visitation Interview Questions 
Questions for PI (Dr. Johnson): 
1. How did you decide that you want to be a professor at a primarily undergraduate 
institution (PUI) such as Hope College? 
2. In your opinion, what are the primary differences between running a lab at a 
large, research-intensive university versus a small, primarily undergraduate 
college? 
3. What are the biggest obstacles that you face as a PI at a small university and 
how do you do your best to overcome these challenges? 
4. How do you overcome limitations in time, student experience and resources that 
are often stumbling blocks for many undergraduate research groups? 
5. What is more important to you when running your lab: research or teaching? 
6. Do you believe it is better to constantly supervise younger undergraduate 
researchers or to give them more independence to learn on their own? 
7. How do you recruit and select new students to join your lab? 
8. What are your criteria for selecting research projects? 
9. What advice do you have for someone who hopes to someday be a PI of a lab 
like yours or who wants to modify the structure of an existing lab to be more 
“successful”?  
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Questions for Students: 
1. Why did you decide to join Dr. Johnson’s lab?  What do you plan to do after you 
graduate? 
2. Do you enjoy doing research?  What do you like about it and what do you 
dislike? 
3. Did you get to choose what project you’re currently working on? 
4. Do you agree with Dr. Johnson’s mentoring style?  What, if anything, would you 
change? 
5. Do you enjoy working with the other people in your lab? 
6. How do you feel you learn best, from your own mistakes or from advice from 
others?  Do you prefer receiving advice from co-workers or from Dr. Johnson? 
Why? 
7. Do you prefer working alone or collaboratively? 
8. Do you feel you have enough independence in designing and engaging in your 
own original research?  Do you ever want more guidance? 
9. Do you feel comfortable working in the laboratory? Do you ever feel pressured or 
stressed? If so, why? 
10. On a scale from 1-10, how important is publishing papers important to you? 
11. What is the most important thing you’ve learned from joining Dr. Johnson’s lab?  
What do you still want to learn? 
12. How do you define success as a student researcher?  What do you think has 
been the biggest key to your success as a research group, specifically with 
regards to your number of high impact publications? 
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13. What, if anything, would you change about the Johnson lab? 
 
5.7.2 University of Michigan Visitation Interview Questions 
Questions for Stanna (beginning of exchange program): 
1. How did you become involved in the exchange program? What incentivized you 
to participate? 
2. Do you enjoy doing research?  What do you like about it and what do you 
dislike? 
3. As of right now, what are your plans after you graduate from Hope College? 
4. What are your expectations for working in the Montgomery lab? What do you 
hope to learn? 
5. Do you have any concerns about working in a lab with graduate students or 
about the exchange program in general? 
6. What is your opinion on the exchange program right now? Have you experienced 
any “stumbling blocks” or difficulties? 
 
Questions for Stanna (halfway through exchange program): 
1. How is working in the Montgomery lab going so far? Has it met your 
expectations? 
2. What have you learned from working in the Montgomery lab? What do you still 
hope to learn? 
3. Do you feel like you could have learned what you have learned so far by working 
in the Johnson lab again this summer?  Do you miss anything about working in 
the Johnson lab? 
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4. What is your opinion of the Montgomery lab?  What do you like about it and what 
do you dislike? 
5. In your opinion, compare the similarities and differences between the 
Montgomery and Johnson labs. 
6. Have you become a more or less confident researcher after joining the 
Montgomery lab? 
7. Have you learned anything from your interactions with lab members that is not 
directly related to laboratory skills or content knowledge? 
8. What is your opinion on the exchange program right now? Have you experienced 
any “stumbling blocks” or difficulties? 
 
Questions for Stanna (end of exchange program): 
1. Describe your overall experience working in the Montgomery lab this summer.   
2. Did the exchange program meet your expectations? Are you glad you 
participated? 
3. What did you learn from working in the Montgomery lab?  If there anything that 
you wished you had learned that you didn’t? 
4. Do you feel like you could have learned what you learned by working in the 
Johnson lab again this summer?  Did you miss anything about working in the 
Johnson lab? 
5. What is your opinion of the Montgomery lab?  What did you like about it and what 
did you dislike? 
6. In your opinion, compare the similarities and differences between the 
Montgomery and Johnson labs. 
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7. Have you become a more or less confident researcher after working in the 
Montgomery lab? 
8. Did you learn anything from your interactions with lab members that is not 
directly related to laboratory skills or content knowledge? 
9. Do you think your feelings about research have changed after working in the 
Montgomery lab?  Have your career plans changed at all? 
10. What is your overall opinion on the exchange program? Did you experience any 
“stumbling blocks” or difficulties? 
11. If you could change anything about the exchange program what would you 
change? 
 
Questions for Stanna (~2 months after completion of exchange program): 
1. Have you felt that the exchange program has helped you in your time since 
you’ve been back to Hope? If so how? 
2. Have any of your thoughts/feelings about the program changed since we last 
spoke? 
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